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Abstract 
 
Gas biomarkers are receiving increasing attention across the field of human gut health. 
The gas production profiles of the gut can potentially be used for diagnosis, assessment, 
and monitoring of gut diseases and disorders but also have other applications in 
assessing gut-health related issues such as the investigation of diet effects and 
digestibility of foods. The processes of the upper gut have a large impact on the lower 
gut health. To gain a unique perspective and understanding on the impact that food has 
on a person’s gut health and well-being, it is critical to comprehend the gut’s bio-
chemical and bacterial interactions. To gain such information, a platform wherein 
simulated digestive that allows gas production analysis to be performed in real-time on 
food is required. More importantly, this digestive simulator is capable of revealing the 
mechanisms regarding the food interaction with the digestion system by establishing the 
link between the digestive processes and gas production behaviours within the gut. As 
the result, the choice of ingredients used in a food product can be based on the outcomes 
of ‘digestion positive’ gas production profiles leading to new and improved food 
products that are more friendly to the gut. Furthermore, in the prospect of the 
gastrointestinal fields, understanding the food related gas production kinetics within a 
simulated digestion system is an economical and safe method, allowing the 
identification of abnormal digestive processes linking gas production profiles to health 
outcomes such as diagnosis, monitoring, and dietary management for people with gut 
disorders. 
The aim of this research is to broaden and enhance our knowledge of gas production 
mechanisms that occur within the upper gut and their link to their digestive processes. 
This was achieved by designing, evaluating and establishing an in-vitro upper gut 
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digestion simulator capable of monitoring real-time gas production and pH profiles. 
This was first investigated via thorough literature reviewed the current in-vitro digestion 
simulators and digestion protocols, specifically designed for the upper-gut. The design 
and proof-of-concept of the in-vitro digestion simulator was evaluated. Secondly, 
improvements cited from the evaluation was made and the in-vitro digestion simulator 
demonstrated its capacity to be a potential diagnostic tool for investigating gas 
production outcomes. Lastly, the in-vitro digestion simulator explores the idea of upper-
gut disorders as the fermentation capacity of a simulated upper-gut is investigated with 
two different bacteria models. 
In the first stage of the author’s research, a thorough literature review for the upper gut 
in-vitro digestion applications was undertaken. The use of gas biomarkers in the upper 
gut was primarily observed from a bio-chemical digestion perspective. Current upper 
gut digestion simulators with gas measuring capabilities are offline or have long 
sampling periods typically more than 1 h, therefore missing important temporal gas 
production information related to digestion processes mechanisms. To address this gap, 
an upper gut digestion simulator that was low cost, easy operation and capable of 
simulating multiple digestion phases was outlined, designed, and initially evaluated 
based on the digestion outcomes of three well known carbohydrates - glucose, fructose, 
inulin. The author’s upper gut digestion simulator was able to demonstrate and identify 
gas production from multiple digestive mechanisms occurring from both bio-chemical 
and bacterial sources from the gas production profiles. Results of the evaluation were 
compared with the literature and found to be consistent with the outcomes regarding 
carbohydrate digestion. 
Followed by the evaluation of the author’s upper gut digestion simulator using the 
known carbohydrate species, the digestion simulator was explored as a potential 
  
iii 
 
diagnostic tool based on the investigation of upper gut gas production. This was 
achieved by simulated digestion of cow’s milk, a highly consumed food-type which has 
clinically been observed to cause bloating and excessive flatus. The simulations 
investigated the gas production outcomes of several scenarios including the impact of 
adding a simple bacteria model and the presence of lactase. Digestive outcomes of the 
simulation were aligned with clinical studies outcomes demonstrating lowest production 
of quantities of gas occurred with the presences of lactase, caused by low bacteria 
populations. Conversely, high gas production outcomes were observed with high 
bacteria populations without lactase. Confirmation of digestion in-vitro – in-vivo 
similarities were observed via breakdown of the milk food-matrix as observed via 
Raman analysis. Bacterial metabolic activity was also observed via NMR metabolomic 
analysis. 
 
The final stage of the author’s research investigates the simulator’s capacity to explore 
gas biomarkers within a simulated upper gut disorder. The chosen disorder was a 
symptom known as small intestine bacterial overgrowth, wherein lower gut microbiome 
is able to establish itself within the upper gut significantly impairing nutrient absorption 
and proper digestive functionality. The use of the three model carbohydrates were used 
as well as another bacterial model to represent the lower SI gut microbiome. With this, 
gas production outcomes were investigated across representative models of the upper 
and lower gut at 106 CFU and 109 CFU concentrations. Outcomes of the investigation 
revealed that bacterial diversity was a large factor as increased CO2 and H2 production 
for the lower SI model despite same bacterial population inoculum size. Inulin 
demonstrated unique ‘double peak’ feature within the CO2 rates of production for the 
lower SI bacterial model. The magnitude of the second peak directly related to the 
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bacteria’s inoculum size. The inulin simulations also reflected a time ‘delay’ feature in 
H2 production with respect to the bacterial model used. The glucose CO2 production 
also reflected unique profiles with slower fermentation rates. Fructose CO2 production 
was the complete opposite with large CO2 production immediately after the phase 
transition. Short chain fatty acid profiles also reflected a trend indicating that 
significantly propanoic acid increases with lower SI bacteria model population size. 
Despite the limitations of an in-vitro approach, there are a number of gas biomarker 
trends and features that were observable with real-time gas production monitoring. 
 
The insights and technological advances achieved in this PhD research are expected to 
contribute significantly to the advancement and understanding of gas production 
mechanism within the upper gut. In particular, this was achieved by creating new, 
simple, accurate and reliable technologies, while significantly contributing to the 
knowledge of in-vitro digestion simulation systems and their applications. 
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Chapter 1 - Introduction 
1.1  Introduction 
Gas biomarkers are receiving increasing attention across the field of gut health [1]. The 
gas profiles of the gut can potentially be used for diagnosis and monitoring of certain 
gut disorders including irritable bowel syndrome (IBS), and small intestinal bacterial 
growth (SIBO) to name a few [2]. Gas biomarkers also have other applications in gut 
health related to the investigation of diet and digestion of foods [3]. To gain an in depth 
understanding on the impact of diet on a person’s gut health and well-being, it is critical 
to comprehend the gut’s biochemical and bacterial processes as well as the by-products 
produced from these processes. Further investigation of the dynamic process that create 
these biomarkers are required to be able to make links to key digestive activities of the 
gut with specific biochemical or bacterial processes. As gas production occurs within 
every step of digestion, gases of the gut have the potential to further increase our 
understanding of the behavior of the gut. 
In this PhD research, the main focus is on the development of a novel in-vitro digestion 
simulator that measures gas production profiles at a high enough sampling rate to start 
to understand some of the key dynamics in the creation of these gases. This provides the 
means to link key digestive mechanisms with unique gas production profile features as 
well as understand how specific food-types can influence gas production output. Some 
of the guiding parameters to the design of the in-vitro digestion simulator is that it’s set-
up is cost effective, reliable, reasonably portable.  
The author’s in-vitro digestion simulator was first trialed using three well studied model 
carbohydrates (glucose, fructose, and a long chain fructo-oligosaccharide known as 
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inulin) to assess the gas sensing capability and other design parameters of the in-vitro 
digestion simulator. 
 
The candidate then explores some of the potential of the author’s novel in-vitro 
digestion simulation by comparing digestive outcomes of cow’s milk (referred to from 
here as milk) with the current literature. Several digestive scenarios were investigated 
which included a simple bacteria model (SBM) and the impact of the lactase enzyme. 
Digestion scenarios where excessive gas production was observed within the in-vitro 
simulations were align with published literature and clinical observations which 
demonstrated the validity and potential application of the author’s in-vitro digestion 
simulator.  
 
As the last stage of this PhD research, the in-vitro digestion simulator was used to 
investigate a simulated upper gut disorder called small intestinal bacterial overgrowth 
(SIBO). Another bacterial model (the multi-strain bacterial model or MSM) was 
introduced representing strains in the lower SI/cecum regions (lower gut) where 
bacterial fermentation is the dominant source of gas production. A simulation matrix of 
SBM (simulated native SI flora) and MSM (simulated non-native SI flora) versus low 
and high bacterial population size was evaluated against the three model carbohydrates. 
The introduction of ‘rate of production’ profiles were additionally added as a way to 
further increase the amount of trends and features obtainable from in-vitro digestion 
systems and gas biomarker. The gas production and rate of production profiles reflected 
clear, repeatable trends and features that were able to demarcate the low bacteria non-
native SI and high bacteria non-native SI simulations. 
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A detailed background and justification regarding design and research choices of the in-
vitro digestion simulator are presented as follows. 
 
1.1.1 Gas as a biomarker for health 
In general, gas has been used as a health biomarker for centuries [2]. It was initially 
conducted via ‘smell’ of larger aromatic gas molecules with records of Hippocrates 
using a patient’s odour as a tool for diagnosis [2]. Additionally, it was documented that 
the diagnosis of the ailment Diabetic ketoacidosis was made via smelling a sweet, 
fruity-smell on the patient’s breath [4]. This concept of ex-vivo aromatic gas detection 
was advanced further with Nobel laureate Linus Pauling’s work describing the complex 
mixture of volatile compounds present in breath and urine samples [5].  
 
While these discoveries were important, an in depth understanding of gas production 
mechanisms within the gastrointestinal tract were lacking. To this end, significant 
research was conducted initially using animal gastrointestinal tracts as a model [6]. 
Investigation was then moved onto the human gastrointestinal system with Levitt et al. 
[7] observing large quantities of gas production within the large intestine was primarily 
due to the enormous bacteria population. Further links between gas species and 
production quantities were subsequently linked to the consumption of specific food-
types. Currently, it has been widely accepted that throughout the gastro-intestinal tract 
(GIT), hydrogen (H2), carbon dioxide (CO2), and methane (CH4) are important 
functional gases of the gut that are found at relatively large concentrations [7, 8]. 
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1.1.2 Gas production within the gut 
Gas production within the GIT is specifically a result of biochemical reactions and 
bacterial fermentation along the passage of the gut. Gas production at the beginning of 
the digestion process is primarily dominated by biochemical reactions. Little-or-no gas 
production occurs during the mastication of food or the formation of food bolus within 
the mouth. This can be attributed to the extremely short transit time (10s – 5 minutes [9, 
10]) and the small bacteria population within the mouth (<103 CFU [10]). The food 
bolus is transported via peristaltic contractions through the esophagus where it enters 
the stomach. Here, the food bolus interacts with the acidified gastric juices which 
contain hydrochloric acid (HCl), electrolytes, and a variety of digestive enzymes, which 
predominantly is constituted of pepsin [11]. Food content within the acidified gastric 
juices is chemically broken down and enzymatically cleaved. It has been observed that 
CO2 production occurs within this stage as the quantity of production is highly 
dependent on the food types under gastric digestion [12]. After sufficient time within 
stomach, the gastric contents (also known as gastric chyme) transitions into the 
duodenum where it is mixed with bile and pancreatic juices. This mixture contains a 
wide assortment of digestive enzymes which include a more powerful variant of 
amylase, protease, and lipase to completely cleave the remaining food molecules 
making them ready for absorption. There are also large quantities of bicarbonate ions 
which neutralize the acidic components within the chyme which result in CO2 
production [13]. At this stage of the digestion, the source of gas production that occurs 
is still primarily biochemical but small populations of bacteria also known to metabolise 
transient digesta. As the digesta transits through the small intestine, the bacterial 
population size and complexity start to increase resulting in a gradual shift towards 
bacterial fermentation. The small intestine region is comprised of two main sections – 
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the proximal small intestine known as the jejunum which has a bacterial population of 
between 103 CFU/ml - 106 CFU/ml [14]. The second section is the distal small intestine 
called the ileum, which, comprises of a bacterial population typically between 104 
CFU/ml - 109 CFU/ml [14, 15]. Gas production occurs from bacterial fermentation but 
is limited due to the digesta’s short transit time which is typically 1 – 2 h but is highly 
dependent on the food-type consumed [16]. Finally, the remaining digesta enters the 
large intestine where it is rapidly fermented by the enormous resident bacterial 
population. There population size within the large intestine is between 1012 CFU/ml – 
1014 CFU/ml and the primary source of gas production that is produced is bacterial in 
source [16, 17].  
 
1.1.3 Current methods of gas measurements on the gut  
Currently, many in-vivo and ex-vivo gas measuring techniques have been employed to 
research this complex system within the GIT. Some of the technologies used to measure 
gas production from the GIT are: the swallowable gas sensing capsule [18], calorimetry 
chambers [18], direct intubation [19], and gas composition analysis of expired breath 
(also known as breath tests) [20] as well as many medical imaging techniques [21, 22]. 
One of the primary dilemmas with non-invasive ex-vivo approaches is that gas 
measurements are always observed at the end of GIT revealing little about the important 
processes that food stimulus undergo during digestion [23, 24]. The in-vivo techniques 
that probe deeper into the GIT are often associated with higher patient risks, extensive 
ethics requirements, large volunteer base requirements, and the need for highly trained 
staff in attendance during the experiment trials. While greater use of technology helps to 
reduces some of the barriers, the more in depth in-vivo based investigations ultimately 
suffers from protracted experimental time periods, large patient-material overheads and 
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high financial costs. Further still, current ex-vivo and in-vivo measurement techniques 
struggle to explain the wide variability in baselines and obtained gas production 
measurement profiles which is a result of the internal digestive processes that food 
stimulus undergoes [25].  
 
1.1.4 In-vitro digestion systems 
A powerful investigation method to help explain the inner processes that food stimulus 
undergoes is to model them using in-vitro digestion simulators. These systems are 
popular tools for the exploration of specific digestive functions due to repeatability, cost 
effectiveness, and the ability to control the environmental conditions [14, 26]. As such, 
the complexity of in-vitro digestion systems is typically represented by environmental 
parameters used for emulating the gut including chemical mix of digesta, enzymatic 
content, pH, anaerobic conditions, and complexity of bacterial models [26-30]. These 
in-vitro digestion simulators have been widely used across many fields including 
pharmacology [31], immunology [32], dietetics [33], and gastroenterology [34]; 
primarily for assessing the impact of specific stimulus has on digestive functionality. 
Ultimately, in-vitro digestion simulators can be divided into three main categories: 
static mono-compartment, dynamic mono-compartment, and; dynamic multi-
compartment [14]. 
 
1.1.4.1  Static mono-compartment simulators 
These digestion simulators are typically characterised as utilising only a single 
fermentation reactor for chemical and enzymatic digestive analysis applications. They 
are widely used due to the setup simplicity, high through-put, high repeatability, and; 
are easily customisable.  This enables the static mono-compartment digestion simulator 
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to emulate a wide variety of GIT functionality, including multiple digestive phases. 
Additionally, users of these static mono-compartment in-vitro digestion systems don’t 
require specialist training. 
Despite the potential of this type of in-vitro simulator, a very large drawback is its 
inability to include ‘dynamic’ aspects of digestion. Examples of these are simulated 
mastication of food or strong peristaltic motion within the gut which effects food 
particle size. Other limitations of this system include the orocecal timing and transition 
mechanism - the peristaltic movement of digesta between digestive organs [14]. These 
types of in-vitro digestion simulators are good at investigating the effects and impact of 
specific digestive events. 
 
1.1.4.2  Dynamic mono-compartment simulator 
Several electro-mechanical systems were created to incorporate the ‘dynamic’ aspects 
of digestion with their main aim to incorporate the mechanical-digestive actions that 
break food structures into smaller molecules. These dynamic mono-compartment 
simulators include food mastication mechanisms [35, 36] and gastric peristalsis [37, 38] 
to investigate the impact on digestion. These dynamic simulators were able to 
demonstrate that larger or denser food particles take longer to break down into their 
mono-constituent forms [39-41].  
While simulating this aspect of digestion brings the in-vitro systems a step closer to 
human digestion, the cost and complexity of these simulators are also increased and 
require additional training to be used. Also, due to the electro-mechanical installation 
within the compartment, only a single digestive phase (e.g. oral or gastric phase) could 
be simulated. 
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1.1.4.3  Multi-compartment simulators 
These simulators are effectively the combination of multiple static or dynamic mono-
compartment simulators. More advanced versions of the dynamic multi-compartment 
simulators use programmable peristaltic pumps to simulate the orocecal transit aspects 
[42]. Complex control systems are required to regulate many parameters in the 
simulation including: temperature, pH in the gastric and duodenal phases, digestive 
phase emptying rates, and injection rates of simulated digestive juices. These 
parameters are typically based on in-vivo collated data but have the potential to be 
varied for research and investigative purposes. These systems have been mostly 
standardised and validated for specific applications, such as the study of gastric 
medicinal activity [43] or the survival of probiotics [44]. Fundamentally, these in-vitro 
digestion system that emulate many of the in-vivo behaviours are highly sought after as 
it is the closest representation to the human GIT. Despite this, the complexities of such 
an advanced in-vitro digestion systems also constitute some of its disadvantages.  These 
include high level specialist training for operators, large scale operation costs and low 
throughput. The simulation complexity is still fundamentally limited due to the 
chemical and enzymes which are difficult to replicate [45-47]. 
 
1.2  Motivation 
Within the gut health and diet space, researchers are largely investigating the link 
between macronutrients and specific food-types on the gas production profiles 
generated from the large intestine microbiome. Strong links between gut disorders and 
altered gas production profiles have been observed [48]. The use of in-vitro digestion 
systems in this gut-health space facilitates the ability to simulate gas production kinetics 
of the large intestine within a controlled environment. Typically, an in-vitro digestion 
  
9 
 
simulator with gas sensing capabilities is used in combination with a human fecal-based 
slurry which represents the donor’s microbiome. The addition of the food-types under 
investigation is added to the in-vitro simulation and the gas production is periodically 
monitored. However, the in-vitro systems that are currently used within this field are 
equipped with modules that measure the total volume of gases produced [48] or 
measure headspace gas constituents that are sampled between 1 to 6 h increments [8]. 
So far, in-vitro digestion systems do not incorporate continuous gas measurement 
capabilities. For this critical reason, the current analysis by such systems misses 
important temporal gas production information relating to source of production, namely 
chemical, enzymatic, or bacterial fermentation [49].  
 
Further still, little is understood about the chemical and bacterial gas production kinetics 
of the upper gut digestion. Due to the small quantities of bacteria within the upper gut, 
very little attention to gas production have been investigated [50]. The upper-gut plays a 
critical role in digestion as the processes that occur greatly impact on food absorption in 
the small intestine or is passed into the large intestine for bacterial fermentation. The 
possibility of linking gas biomarkers to upper gut digestive behaviors vastly broadens 
the quantity of digestive information that can be acquired. 
 
To overcome the aforementioned gap, this research introduces a novel in-vitro digestion 
simulation system that can record gas production and pH in real-time. Here, the author 
develops a mono-compartment reactor that is capable of simulating the oral, stomach 
and small intestine (SI) phases of digestion. The formulation of the simulated digestive 
fluids, including the explored enzymatic content, used in the presented study is based on 
the work of Minekus et al. [9]. An added bacterial model is used within this small 
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intestine phase to help provide a better perspective of the impact and effects of gas 
production contributions that occurs with the food stimulus. 
 
1.3  Objectives 
This thesis is primarily focused on developing a novel upper gut in-vitro digestion 
simulator that can reveal more ‘digestive’ information via high sample rate gas 
production information. The research work within this PhD thesis can be briefly 
classified under the following objectives: 
• Introduce and evaluate a novel, low-cost, real-time, gas sensing equipment that 
allows that facilitate the multiple digestive phases that occur within the upper 
gut  
• To accurately produce the real-time gas production profiles from an array of 
sensors, identifying key gas production features relating to upper gut digestion 
parameters. 
• Investigate where the source of gas production throughout the three phases of 
upper gut digestion (either chemical reaction or bacterial fermentation)  
• To validate and establish the in-vitro digestion system as a potential tool for 
investigation gas production within the upper gut 
• Investigate potential upper gut scenarios in which gas production may occur for 
applications purposes within the field of gut health. 
 
1.4  Thesis organization 
This thesis is primarily dedicated to the design and application of the in-vitro digestion 
system equipment and digestion protocol for upper gut digestion. The main focus is to 
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improve the amount of ‘digestive’ information, in the form of gas production 
observations and key features that can be delivered by real-time sampling. 
In chapter 2, the author’s novel in-vitro upper gut digestion simulator is outlined. The 
methodology of the thesis is explored and explained through the in-vitro digestion 
simulator type, choice of sensors, digestion protocol, and other peripherals required to 
calibrate the simulator. 
 
In chapter 3, evaluation of the author’s developed digestion simulator was assessed 
using three well-studied model carbohydrates: glucose; fructose; and inulin. The gas 
production profiles and other digestion by-product characterisation was successfully 
compared with the literature available. Several potential improvements were also 
observed to improve the gas measurement sensitivity. 
 
In chapter 4, the potential improvements observed in the previous chapter were made to 
the author’s in-vitro digestion simulator. The simulator was demonstrated as a proof-of-
concept using milk which is well studied for both its nutrition and its gut-gas symptoms 
(e.g. bloating, excessive flatus). The gas production profiles and digestive 
characterisations were aligned with current literature and clinical observations. 
 
In chapter 5, the author uses the established novel in-vitro digestion simulator to further 
investigate the bacterial fermentation capacity of the upper gut. This was achieved via 
simulation of the three model carbohydrates (glucose, fructose, inulin) with two 
different bacterial models representing the proximal small intestine (SI) and the other, 
distal SI. They were also investigated in low and high bacterial population sizes. Gas 
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production profiles were measure and rate-of-production profiles calculated to 
investigate the differences between bacterial models.  
 
Finally, in chapter 6, the author presents the concluding remarks and the future outlook 
of the research presented in this thesis. 
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Chapter 2 - In-vitro digestion simulator protocol, design, 
equipment, and materials    
2.1  Introduction 
In the previous chapter, the candidate outlines the need for the development of a novel 
in-vitro digestion system for the upper gut with the primary aim of broadening the 
current understanding of gas production and the impact that present bacteria have on gas 
production. The use of gases within the gut has been recognised a biomarker for 
investigating, assessing, and diagnosis of gut health. A brief history was outlined 
regarding the use of gas biomarkers starting with large aromatic molecules via smell [1]. 
More specific gas species in the form of volatile organic compounds were later 
discovered from breath and urine samples [2]. With more advanced technologies, the 
ability to sense a variety of gas profiles within the gut provided new insights into gut 
health [3]. As such, a large problem with in-vivo experimentation was the protracted 
delays, the requirement for ethics approval, and; large overall financial costs. Further 
still, in-vivo experimentation struggles to explain the large variance in datasets which is 
typically a result of specific digestive functionality within the gut. As such, in-vitro 
digestion simulations can be a powerful tool for the exploration and understanding of 
specific digestive functions due to its high customisability and flexibility in simulating 
the digestive environments. 
 
In this chapter, the author describes the development of the novel real-time gas 
production monitoring upper gut in-vitro digestion simulator. The developed upper gut 
in-vitro digestion system is capable of chemically simulating (including enzymatic 
content) the ‘upper gut’ digestion, and; is able to reveal additional ‘digestive’ 
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information than the current in-vitro digestion simulators via real-time temporal-gas 
production profiles. This is used to observe gas production and identifying key gas 
production features and trends associated with the food-types. A comprehensive 
discussion about the digestion simulator design specifications, configuration, gases 
sensed, sensors technologies, and digestion protocol is follows.  
 
In brief, the chosen digestion simulator configuration was based on the mono-
compartment design due to its ability to simulate chemical and bacterial digestive 
systems in a compact form and thus making large scale batch simulations possible. The 
gas sensors used within the digestion simulator were a non-dispersive infrared (NDIR) 
sensors for measuring CO2 for their high selectivity. For H2 sensing, a thermal 
conductivity calorimetric gas sensor which is capable of measuring ppm levels within 
an anaerobic environment, and; a liquid-electrolyte based electrochemical sensor for 
oxygen (O2) measurements to ensure an anaerobic environment during the simulation.  
 
2.2  Design Considerations 
The upper gastrointestinal tract consists of many different organs that primarily aid in 
the breakdown and absorption of nutrients from food consumption. The digestive 
processes that occur within the upper gut are critical for nutrient absorption and largely 
impact on the digesta content that transit into the lower digestive tract. The three major 
digestive areas within the upper gut can be considered to be the mouth, stomach, and 
small intestine regions [4, 5]. The gas constituents and concentrations found in the 
upper digestive tract are discussed followed by the discussion of gas sensors to be used 
within the simulator. 
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2.3  Gas composition  
2.3.1 Oral phase 
Excreted breath contains over 200 volatile organic compounds (VOCs) [6]. These 
compounds typically range from hydrocarbons, alcohols, ketones, and aldehydes at 
parts per trillion (ppt) to low parts per million (ppm) in concentration.  
 
Despite the variety of gas species expelled via the breath, the predominant gas 
constituents within the mouth more closely resembles the composition of atmospheric 
air [7, 8]. This is attributed to the constant exposure of atmospheric air via the mouth 
and nasal passages. There are moderate quantities of bacteria (<103 CFU/mL) within the 
mouth. However, due to swallowing action and saliva constantly washing over the 
surfaces of the mouth, as well as O2 exposure (oxidative stress), very little fermentation 
gas occurs [9]. 
 
2.3.2 Gastric phase 
Again, the composition of gas found within the stomach closely resembles that of the 
atmosphere [10]. This is due to the swallowing of air during food consumption. Also, 
residual air in the oesophagus via breathing is peristaltically pushed into the stomach.  
 
Specific CO2 production has been observed during the digestion process due to the 
saliva-gastric acid interaction as part of the digestion process. Bicarbonate (HCO3-) ions 
present within the saliva interact with the hydrochloric acid (HCl). This chemical 
interaction is known as the acid neutralisation reaction is described in equation (1) [11]. 
 
  
22 
 
𝑁𝑎𝐻𝐶𝑂3 + 𝐻𝐶𝑙 ⇁ 𝑁𝑎𝐶𝑙 + 𝐶𝑂2 + 𝐻2𝑂 (1) 
Partial CO2 pressures have been measured for a variety of meals in-vivo but due to the 
inter-variability of stomach volume between volunteers, is difficult to specify the CO2 
concentrations [12].  
 
2.3.3 Small Intestinal phase 
From the stomach, the gastric digesta enters the duodenum in which large quantities of 
intestinal digestive juices are released. High concentrations of NaHCO3 are found 
within these digestive juices which reacts with the free H+ ions and HCl content which 
follows the acid neutralisation reaction from equation (1). This chemical interaction 
results in large quantities of gaseous CO2 and other by-products [11]. According to the 
studies conducted by Levitt et al. [7, 8] - for a typical (western) meal, the interaction 
between gastric digesta and NaHCO3 can produce 600 mL of CO2. Further still, 
triglyceride digestive processes result in the release of free fatty acids which also react 
with the NaHCO3, promoting additional CO2. Aside from increasing CO2 production 
associated with the gastric digesta – intestinal juices interaction , it has been observed 
that the pO2 concentrations steadily decrease as digesta progresses through the gut[13]. 
Towards the end of the distal SI region, the overall O2 concentrations approach 
anaerobic levels. 
 
As part of the investigation conducted by Levitt et al.[7, 8, 10, 14], he observed no 
measurable H2 production from the SI which he attributed to the low bacteria 
populations in combination with high transient environment of the SI. Despite this, 
quantities of H2 has been clinically observed in the expired breath for the assessment of 
bacterial related upper gut disorders [15]. In a healthy gut, there are lower levels of 
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bacteria that naturally inhabit the SI suggesting that H2 production does occur within the 
upper gut [16]. Also, considering the technology used during the period of investigation, 
it is highly possible that the equipment used was not sensitive enough. Despite the 
literature suggesting that H2 is not produced within the SI, H2 will be attempted to be 
observed as another potential gas biomarker for the SI. 
 
As such, CO2 and H2 are gases that will be primarily focused on throughout the in-vitro 
digestion simulation investigations. 
2.4  Gas measuring technologies 
There are many types of gas measuring technologies available for the detection of 
various gas species and concentrations. Broadly speaking, these gas measuring 
technologies can be split into two categories - stationary measuring platforms and 
portable measuring devices.  
 
The stationary measuring platform technologies prioritise high accuracy and large 
flexibility in their field of applications which is achieved via the integration of 
physically large but high precision metrological equipment [17, 18]. Such high 
precision equipment is ideal for laboratory environments where experiments can be 
conducted within the physical location of the stationary measuring platform for 
analysis. Such platforms include gas chromatography (GC) [19, 20], mass spectrometry 
(MS) [21, 22], and large optical based sensing platforms [23-25]. 
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Table 2.1 - Summary of the most common gas analysis technologies capable for in-vitro 
gas measurements. Table section have been reprinted with permission from reference 
[26] 
Technology Target 
gas 
Detection 
limit 
Cross-
sensitivity 
Response 
time 
Estimated 
cost 
Spectrometry based measurement 
GC-MS All gases ppb - ppt  Low >1 min >US$ 300k 
IMS All gases ppb Low <1 min >US$ 100k 
PTR-MS All gases ppt Low <1 min >US$ 400k 
SIFT-MS All gases ppb Low <1 min >US$ 400k 
LS 
Most 
gases 
except H2 
ppb - ppt 
Low <1 min <US$ 50k 
Sensor based measurements 
Electrochemical 
H2, H2S, 
NO, and 
CO2 
ppm Medium <30 s <US$ 100 
Calorimetric 
H2, CH4, 
and CO2 
ppt High <10 s <US$ 100 
Non-dispersive 
infrared (NDIR)  
CO2, 
CH4, and 
VOCs 
ppm to ppt Low <20 s <US$ 300 
 
 Some disadvantages of stationary measuring platforms are the large overheads and 
financial costs for the equipment and infrastructure requirements for installation and 
operations (e.g. laboratory facilities and additional equipment for high purity gases like 
N2, Ar, H2 required for analysis). Further still, the flexibility and diversity that makes 
stationary measuring platforms diverse requires high levels of user training to ensure 
high-confidence measurement capabilities. For experiments that can be in close physical 
proximity to the stationary measuring platform, measurements can be obtained in quasi 
real-time (long sampling periods) but required the addition of highly specialised 
equipment which is costly.   
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For gas measuring applications that are required for in-situ measurements or a small 
form factor unit for multiple site measurements, portable measuring devices are more 
advantageous.  The reduced size and compactness of gas sensor technologies that enable 
the portable measuring devices to be mobile and small form factor. The gas sensor 
technologies have the ability to provide high accuracy measurements but compromises 
measurement range and/or sensitivity of the measurements. However, these portable 
systems and sensors have a large advantage in that they are highly mobile, minimal 
infrastructure requirements (either wall or battery powered), and; are very low cost 
(Table 2.1). 
 
As part of the scope of this PhD research project, the design of the upper gut in-vitro 
digestion simulator targeted a portable solution as a low-cost alternative that does not 
required the need of a stationary gas measuring platform for analysis. As such many 
sensors were initially researched for use within the in-vitro digestion simulator [27-29]. 
The reactor was chosen to be anaerobic in design as the primary aims was to 
specifically measure the gas production from the chemical and bacterial sources within 
the simulation. A list of common methods of gas concentration measurements are listed 
in Table 2.1.  
 
Based on their cost and portability, the field of gas sensors were narrowed to the optical, 
electrochemical, and calorimetric technologies. A discussion of the previously 
mentioned sensing technologies was outlined with their reasons for choice within the in-
vitro digestion simulator outlined. 
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2.4.1 Optical gas sensing technology  
Optical based gas sensors take advantage of the unique gas molecule wavelength-
absorption relationship. Typically, optical gas sensing technology relies on a 
spectrographic approach to observe absorption within specific wavelength bands from a 
narrow or broad-spectrum light source, which can link gas concentrations to the 
magnitude of absorption measured. Practically, the generation of the optical specific 
wavelength, specifically narrow band wavelengths, require bulky, costly and 
sophisticated instruments to enable operations. Many varieties of optical based sensors 
have been used including fibre optics and interferometry [30, 31], chemilumiscence [32] 
and, tunable cavity laser-based sensors [33].  
 
Miniaturisation of these sensing platforms for commercialisation is achievable but 
results in reduced gas sensing sensitivity and selectivity. However, the portable nature 
of the optical based sensor makes its uses and applications highly versatile. An example 
is the NDIR (Non-Dispersive Infrared) optical sensors which has lower costs and 
smaller size and complexity. However, the NDIR sensor has a reduced selectivity loss 
[33]. Despite this fact, the sensitivity and selectivity are high enough for use in many 
areas including bio-gas applications and are also good candidate for in the in-vitro 
digestion simulator. There NDIR sensing range satisfy the requirements for sensing CO2 
gases in concentration ranges suggested by Levitt et al. [10].  
 
2.4.2 Electrochemical gas sensing technologies  
Electrochemical sensors consist of an electro-chemical cell with either a two or three 
electrode configuration, whose electrolyte chemistry reacts (either via oxidation or 
reduction) to the target gas analyte at set potential. The reaction can result in either an 
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amperometric or a potentiometric response, depending on the technology of 
electrochemical sensor used. These sensors are typically sealed with a non-specific gas 
permeable membrane that allows gases (including the target analyte) to pass through. 
The electrolyte chemistry within the electrochemical sensor can be categorised into two 
specific technologies - liquid and solid electrolyte-based. Typically, the liquid 
electrolyte based electrochemical sensors are amperometry and the solid-state based 
sensors are potentiometric in sensor response [34, 35].  
 
A small amount of oxygen is required in the counter electrode for the reaction with the 
target gas. For applications within an anaerobic environment, liquid electrolyte based 
electrochemical sensors have an advantage in that, oxygen can be found dissolved in the 
liquid electrolyte. Depending on the volume of the electrolyte, access to this dissolved 
oxygen allows them to operate in the anaerobic environment for several hours before 
being inoperable.  
 
Electrochemical sensors are available for a variety of gases that could potentially be 
harnessed for the author’s upper gut digestion simulator. However, there operation time 
within the anaerobic environment of the digestion simulation varies on how much O2 
can be dissolved into the electrochemical gas sensor. This unfortunately, is 
predominantly dependent on the electrolyte chemistry within the sensor and can inhibit 
the electrochemical reactions within the sensor providing lower readings that currently 
present [36]. 
 
However, the specific detection of O2 with an electrochemical sensor does not suffer 
this problem as the sensing analyte is also the component needed to facility the 
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electrochemical reaction. As such, low-to-zero levels of O2 within the reactor will not 
inhibit the electrochemical O2 sensor’s output making it a good candidate. 
 
2.4.3 Calorimetric gas sensing platforms  
The range of calorimetric gas sensors work on the principle of potentiometric changes 
that are a result of thermal transfer from the principle sensing mechanism [37]. 
Calorimetric gas sensors are predominately based on two main configurations - 
catalytic-bead and thermal-conductivity. The catalytic-bead based calorimetric sensors 
utilises a catalytic oxidation of gas species resulting in heat production. The additional 
heat production from the oxidation reaction proportionately changes the resistance of 
the catalytic bead which can be observed via a change in voltage or current. Such 
oxidation reactions required the presences of O2 and as such, this mechanism does not 
function in an anaerobic environment. The thermal-conductivity configuration observes 
the thermal conduction of heat away from an active heating element in the presence of 
the target gas via comparison to a reference heating element. Such a configuration does 
not require the presences of O2 and is also a good candidate for use in an anaerobic 
environment. The sensitivity of a thermal conductivity configured sensor is within the 
ppm range which is potentially a good starting point for measuring H2 production within 
the upper gut simulations.  
 
2.5  Gas production calculation  
Measurements from the gas sensors are given as gas concentrations. Such 
measurements are difficult to draw comparisons as the measurements are relative to the 
headspace volume, headspace pressure, temperature, and type of gas molecule [38]. To 
draw a more meaningful measurement, the gas sensor measurements are converted into 
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absolute quantities of gas production. As such, the gas production profiles were 
calculated according to Rotbart et al. [39] which utilises the ANKOM wireless RF 
pressure monitoring system to aid in gas production calculations. 
 
The pressure within the digestion simulator was maintained and logged wirelessly via 
an off-the-shelf product called the ANKOM wireless RF pressure monitoring system 
(ANKOM, USA). The pressure monitoring units were connected via a HDPE machined, 
GL45 threaded connector and additional Viton gaskets to ensure that the entire system 
was gas tight. Although the importance of pressure distribution along the human GIT is 
still scientifically unclear [3, 40]. Based on studies [41], the pressure that was used 
throughout the digestive simulation was 1 psig. 
 
The total gas production was measured via the real-time pressure changes obtained from 
the pressure transducer. This was converted into transient total gas production volume 
according to both Avogadro’s and ideal gas laws [38]. The gas production of individual 
gas species was calculated according to Dalton’s law [38], in which the total pressure 
exerted is equal to the sum of the partial pressures of the individual gases.  
 
2.6  Simulation experimental design 
There are many types of in-vitro digestion simulators currently used, this is due to the 
specific requirements needed to explore the digestion functionality of interest. A review 
of in-vitro digestion simulations is covered in section – 1.1.4 In-vitro digestion systems 
 
The investigation of the gas production mechanisms within the upper gut require an 
accurate monitoring of the chemical and bacterial processes. However, there is also a 
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mechanical component involved in the upper gut which includes strong peristalsis 
within the stomach and the high transient environment within the SI [42, 43]. Despite 
the importance of the mechanical aspects within digestion, it is key to first investigate 
and understand the sources of gas production within the upper gut. For these reasons, 
the simulator developed for this investigation was a mono-compartment (Figure 2.1) in-
vitro digestion simulator based on the work by Oomen et al.[44].  
 
 
Figure 2.1 - Schematic of the mono-compartment in-vitro digestion simulation set up. 
 
The mono-compartment in-vitro digestion simulator utilises a single, continuously 
stirred reactor to simulate the oral, gastric, and SI phases of digestion. For this reason, a 
modified Schott bottle with a single side (septa) port was used. To ensure that the 
reactor was reliably gas tight during the addition of simulated digestion fluids, a custom 
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machined connector with a one-way check valve was added. The other side of the check 
valve was a Luer lock that securely connected the desired syringes for injection. 
 
For the measurement of gases produced during the digestion simulation, a custom-made 
high-density polyethylene (HDPE) sensor array was equipped. The sensor array was 
machined with four ports to house the different gases sensors and pH probe 
connections. Threads matching the Schott bottle (GL45) were machined into the top and 
bottom segments allowing the reactor to fasten onto the sensor array. Viton gaskets 
were used between the reactor and the sensor array to form a gas tight seal. The sensors 
used in this system were: IR15TT-R for sensing CO2, VQ546M for H2 sensing, and the 
EC410 for measurement of O2. All sensors were purchased from SGX Sensortech 
(Poland). The pH probe was purchased from Sper Scientific (USA). 
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Figure 2.2 – Picture of the in-vitro digestion simulator (3 units), incubator/shaker, and pH meter. 
 
These were connected to custom electronic evaluation boards which amplifies and 
converts the sensor’s output into a digital form. The data was transmitted via a USB link 
to a local computer for data logging. The pH data was recorded to SD-card via a SD-
230 Logging ORP/pH Meter (Rapid Technology, Australia). Three units were 
constructed allowing all digestion simulations to be conducted in triplicates for 
statistical purposes.  
2.7  System calibration  
Three industry calibrated gas cylinders containing 100% CO2, 1% H2 in N2 balance, 
100% CH4 were connected to mass flow controllers (MKS mass flow controller 
1179A). The flow rates through each of the mass flow controllers was controlled by the 
Incubator/Shaker 
pH Meter Sensor evaluation 
boards 
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MKS control unit (MKS 647B). The ANKOM pressure transducer could not facilitate 
the required connections from the mass flow controllers, so a custom made GL45 cap 
was machined with the two gas fittings which formed the gas inlet and outlet.  
 
 
Figure 2.3 - Gas sensor calibration setup - (right) in-vitro digestion unit with machined GL45 cap for gas 
connections; (left) back pressure regulator set to 1 psig to maintain a constant pressure within the in-vitro 
simulator unit chamber 
 
The mass flow controllers connected to the inlet. The outlet was connected to a back-
pressure regulator (K-series, Swagelok) and set to 1 psig (with respect to atmosphere) to 
maintain a constant pressure within the digestion simulator under calibration. 
 
Back Pressure 
Regulator 
Machined GL45 cap (above) 
for gas connections 
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The NDIR and TCD calorimetric sensors were calibrated via the SGX proprietary 
software interface in a two-step procedure. The first step was setting the ‘zero’ point 
which was done by flowing N2 into the reactor. When all the sensors’ raw outputs 
settled and stabilised, the current sensor values are stored onto non-volatile memory 
locally on the evaluation boards. 
 
The second step was to set the NDIR and TCD calorimetric sensor’s span. For the 
NDIR sensor, a 5 %vol mixture was used to calibrate the CO2 component of the NDIR. 
This was achieved by setting the N2 to CO2 flowrate ratio to 20:1. Again, the NDIR raw 
output was observed until stabilisation. The ‘span’ option was activated on the software 
interface. The same process was followed for H2 with the exception that correct 
calibration concentrations were already mixed. As such, there was no need to further 
dilute the H2 mixture. 
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Crosstalk was observed for the TCD calorimetric sensor in the presences of CO2. The 
crosstalk sensitivity was measured at around -0.036 %vol per CO2 %vol. As such, CO2 
crosstalk is calculated out of the final H2 gas production values. 
 
 
Figure 2.4 - The Pellistor and NDIR gas sensor response during in-vitro simulator unit calibration 
 
2.8  Simulated digestive fluids  
Based on the recommendation of Minekus et al. [45], the starting quantities for the 
digestion simulation were chosen to be a 10 mL aliquot of food. Food under digestion 
simulation that are in powder form are mixed with DI water to a ratio of 1:1 (W(g) : 
V(mL)) and are aliquoted into 10 mL portions. Foods in liquid form are directly 
measured out to 10 mL for digestion simulation. Based on the starting aliquot size, the 
  
36 
 
simulated fluids used in the upper gut simulation is outlined in Table 2.2, 2.3, and 2.4. 
All chemicals used to formulate the simulated digestion fluids were of technical grade 
and purchased Sigma (Australia). The digestive enzymes used were purchased from 
Southern Biological (Australia). 
 
All simulated digestion fluids used in the simulations were made on the previous day 
and stored at -20 oC, except CaCl2·[H2O]2 which was added to the simulated digestion 
fluids before the start of simulations. 
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Table 2.2 - List of chemicals used for SSF. 
 Simulated saliva fluid (SSF) 
 Stock concentration pH 7.0 
Constituent g/L mol/L Volume 
(mL) 
Concentration 
(mmol/L) 
     
KCl 37.3 0.5 0.302 15.1 
KH2PO4 68 0.5 0.074 3.7 
NaHCO3 48 1 0.136 13.6 
NaCl 117 2 - - 
MgCl2(H2O)6 30.5 0.15 0.010 0.15 
(NH4)2CO3 48 0.5 0.0012 0.06 
CaCl2(H2O)2  44.1 0.3 0.010 1.5 
DI water   9.467  
     
For pH adjustment of the stock concentration 
HCl 
 
 6 0.018 1.1 
Addition of enzymes  (Per 10 mL SSF) 
 U/mg  mg U  
Amylase 38000 - 
40000 
 0.0039 1140 -  
1200 
Pepsin 8000 - 
10000 
 - - 
Pancreatin (USPx1)     
Amylase activity 25 USP  - - 
Protease activity 25 USP  - - 
Lipase activity 2 USP  - - 
     
The concentrations, quantities used, and solution pH for the SSF with a final volume of 
10 mL. The table has been adopted from the work by Minekus et al.[45] 
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Table 2.3 - List of chemicals used for SGF. 
 Simulated gastric fluid (SGF) 
 Stock concentration pH 2.5 
Constituent g/L mol/L Volume 
(mL) 
Concentration 
(mmol/L) 
     
KCl 37.3 0.5 0.276 6.9 
KH2PO4 68 0.5 0.036 0.9 
NaHCO3 48 1 0.500 25.0 
NaCl 117 2 0.472 47.2 
MgCl2(H2O)6 30.5 0.15 0.016 0.1 
(NH4)2CO3 48 0.5 0.020 0.5 
CaCl2(H2O)2  44.1 0.3 0.0004 0.15 
DI water   18.679  
     
For pH adjustment of the stock concentration 
HCl 
 
 6 0.052 15.6 
Addition of enzymes  (Per 20 mL SGF) 
 U/mg  mg U 
Amylase 38000 - 
40000 
 - - 
Pepsin 8000 - 
10000 
 8 64000 - 
 80000 
     
Pancreatin (USPx1)     
Amylase activity 25 USP  - - 
Protease activity 25 USP  - - 
Lipase activity 2 USP  - - 
     
The concentrations, quantities used, and solution pH for the SGF for a final volume of 
20 mL. The table has been adopted from the work by Minekus et al.[45]  
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Table 2.4 - List of chemicals used for SIF. 
 Simulated intestinal fluid (SIF) 
 Stock concentration pH 8.2 
Constituent g/L mol/L Volume 
(mL) 
Concentration 
(mmol/L) 
     
KCl 37.3 0.5 0.544 6.8 
KH2PO4 68 0.5 0.064 0.8 
NaHCO3 48 1 3.400 85 
NaCl 117 2 0.768 38.4 
MgCl2(H2O)6 30.5 0.15 0.088 0.33 
(NH4)2CO3 48 0.5 - - 
CaCl2(H2O)2  44.1 0.3 0.0064 0.6 
DI water   35.129  
     
For pH adjustment of the stock concentration 
HCl 
 
 6 - - 
Addition of enzymes  (Per 40 mL SIF) 
 U/mg  mg U 
Amylase 38000 - 
40000 
 - - 
Pepsin 8000 - 
10000 
 - - 
     
Pancreatin (USPx1)   320 USP U 
Amylase activity 25 USP   8000 
Protease activity 25 USP   8000 
Lipase activity 2 USP   640 
     
The concentrations, quantities used, and solution pH for the SIF for a final volume of 40 
mL. 15.625 mg/l of dried bovine bile was also added to incorporate 160 mM into the 
SIF. The table has been adopted from the work by Minekus et al.[45] 
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2.9  Simulation protocol 
Numerous in-vitro digestion protocols exist in the literature, each designed to facilitate a 
specific function. Such examples include (but are not limited to) food digestion [46], 
pharmaceuticals [47, 48], or toxicological applications [49]. Generally, these methods 
encompass simulations of oral, gastric and intestinal digestion processes, but the way in 
which physiological conditions are implemented across methods differs considerably 
[50]. 
 
The main requirement from the chosen digestion protocol to accurately observe gas 
production was to represent a standardised chemical and enzymatic composition of 
simulated digestive fluids. The protocol must also allow for flexibility such that, 
digestion specific chemicals, enzymes, or other biological components can be added for 
exploration of digestion function. It is also important that the digestion protocol chosen 
must be well established, founded in robust scientific methodology and highly relatable 
to mono-compartment digestion simulators.  Based on these requirements, the digestion 
protocol chosen was from Minekus et al. [51]. This protocol is a unified digestion 
protocol specifically designed for mono-compartment digestion simulators. Due to the 
popularity of the unified protocol, this provides an established methodology to both 
investigate gas production in the upper gut, and to investigate the impact and effects of 
bacteria in the upper gut. 
 
The digestion protocol of Minekus et al. [51] does not include the use bacteria. As such, 
the protocol was adapted to include the addition of bacteria in the small intestine phase 
which can be seen in Figure 2.5.  
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The digestion simulator unit was assembled via the ‘screw and thread’ type connections 
and rubber gaskets to form a hermetic seal between each component of the digestion 
simulator unit. The seals of the digestion simulator were checked via a pressure test, 
consisting of 50 mL of air injected via syringe into each digestion unit. Units were 
observed over the course of 1 h via the ANKOM RF software for any sudden or gradual 
declines in cumulative pressure. After the units passed the pressure test, they were 
purged with N2 for 12 s to produce an anaerobic environment. The output of the O2 
sensors were monitored to see if the oxygen levels stabilised to less than 3% to assure 
that the headspace environment is of an anaerobic condition. With the units confirmed 
to be gas tight, a 10 mL aliquot of food stimulus was directly injected into the reactor 
via the septa port Luer lock connection and allowed to warm up to 37oC for 20 min with 
gentle agitation (0.5 rpm). This time was also used to equilibrate the reactor and allow 
the sensors to adjust to the headspace content, setting the baseline measurements for the 
TCD calorimetric sensor. Both gas sensors and pH were measured at a sampling rate of 
one sample per second. The pressure transducer sampling rate was software set to the 
fastest rate of one sample every 15 seconds. 
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Figure 2.5 - Up per gut digestion simulation protocol adapted from Minekus et al.[51]. The adaptation to 
the digestion protocol includes the addition of bacterial inoculum to the SI phase. The bacterial inoculum 
was injected after the SIF. 
 
2.9.1 Oral phase 
Simulated saliva fluid (SSF) was prepared using via the method outlined by Minekus et 
al. [51] with the specific materials and quantities used listed in Table 2.2. At this point, 
the reactor should be hermetically sealed and tested for gas leaks. The 10 mL food 
stimulus should also be present within the reactor and the sensors equilibrated. The 
digestion simulation started with the injection of 10 mL of SSF into the reactor, which 
was incubated at 37°C for 5 min with an agitation speed of 0.5 rpm. 
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2.9.2 Gastric phase 
The simulated gastric fluid (SGF) used in the gastric phase was also prepared via the 
method of Minekus et al. [51] with materials and quantities listed in Table 2.3, with the 
following modification to pH. Since the gastric phase directly continues from the oral 
phase, the specific pH of the SGF solution was modified to 2.5 such that, when added to 
the previous phase without any food stimulus, results in the target pH of 3.0. 
  
After the oral phase was complete, 20 mL of SGF was added to the digestion simulator 
unit and further incubated for 2 h. The target pH of the gastric phase was 3.0 and where 
required, 1 M HCl was added to adjust the pH.  
 
2.9.3 SI phase 
Simulated SI fluid (SIF) used in the SI phase was prepared via the method of Minekus 
et al. [51] with materials and quantities listed in Table 2.4. Again, the pH of the SIF 
solution was modified to be 8.2. No additional pH additives were necessary as the 
bovine bile intrinsically sets the pH of the SIF solution to 8.2. When combined with the 
gastric constituents from preceding phases, without the influence of a food stimulus, a 
pH of 7.0 was produced.  
 
After completion of the gastric phase, 40 mL of SIF was injected into the digestion 
simulation giving a total volume of 80 mL digesta. After this process, the resultant pH 
of the small intestine digesta is measured to be between 6.0 - 8.0. This range is seen to 
be reflective of the in-vivo conditions of the small intestine and allows the exploration 
of pH changes directly associated with food digestion [52]. Based on the 
recommendations of Minekus et al. [51], pH adjustments were made with the addition 
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of 1 M NaOH or 1 M HCl. The SI simulation was incubated at 37 o C for a final 2 h. 
The resultant mixture was called SI digesta.  
 
For digestion simulations that were investigating the impact of bacteria - the 106 CFU 
digestion simulations included the addition of 20 µL of inoculum which was added after 
the SIF. Preparation of the bacteria inoculum is discussed in in section - 9.3.1 Use of 
bacteria in the SI phase. 
 
2.9.3.1  Use of bacteria in the SI phase 
The bacteria model used in the digestion simulation investigations consisting of two 
strains - Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07 and was 
sourced in the form of a probiotic capsule (Inner Health Plus Diary Free, Ethical 
Nutrients). The microbiome size and diversity is highly dependent on many factors [53] 
but these particular bacteria, of the phylum Firmicute, have been found at relatively 
high concentrations in the gut and as such, is a good starting point to form a simplified 
model [54] for investigating the impact on gas production during digestion simulations. 
 
The bacterial inoculum was formed by emptying a whole probiotic capsule (25×109 
CFU) into 50 mL of cold (4°C) DI water and gentle mixed until solution changes from 
opaque to semitransparent. The inoculum was then stored at 4°C until required. 
 
Simulations that incorporate bacteria were injected into the reactor during the SI phase 
after the SIF was added. The stored inoculum was prepared for the bacterial simulation 
by incubating (37 o C) for 2 hours prior to the SI phase. This was carried out to 
compensate for the bacterial lag phase. Typically, bacteria levels found in the jejunum 
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are 104 - 106 CFU/ml and 107 - 109 CFU/ml in the ileum [55].  Two concentrations were 
chosen at the upper level of the two ranges to investigate the impact on gas production 
during simulation on both the jejunum bacteria impact and ileum bacteria impact on SI 
digestion. 
2.10   Additional characterisations  
In addition to the real-time gas production profiles and pH, additional characterisation 
was performed on the digesta samples throughout the simulations. The purpose of these 
additional analysis was to two-fold – to observe the breakdown of the food-matrix under 
digestion simulation as gas production events are likely to be linked. Such 
characterisation used to for this analysis are Raman spectroscopy [56-58]. Secondly, the 
additional characterisations provide a perspective into the bacterial behaviour within the 
SI environment and its links to gas production profile events. Bacterial growth assays 
are a well-established method for observing survivability within the SI environment 
[59-61]. Also, the metabolic by-products (particularly the short chain fatty acids) that 
the bacteria produce also provide insight into the bacteria’s ability to ferment the foods 
within the SI phase simulations [62]. Aside from gas production, the bacterial survival 
and metabolic by-products within the SI have a large impact on digestive health [63-
65]. Such analytes were investigated with NMR analysis with the metabolites observed 
in the spectra identified using the Human Metabolome Database [66]. 
2.11  Conclusion 
In this chapter, the author describes the design considerations for the real-time gas 
monitoring upper gut digestion simulator. The outlined development of the simulator 
was comprehensively discussed with the primary aim of the author’s simulator to reveal 
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more ‘digestive’ information that current in-vitro digestion simulators via real-time 
temporal-gas production profiles.  
 
The choice of in-vitro digestion simulator was that of a static mono-compartment style 
simulator as the versatility allows for multiple phase simulations. The digestion protocol 
to match the choice of in-vitro simulator was set out by Minekus et al.[51]. This 
particular digestion protocol is well-established and was designed around the static 
mono-compartment simulator with simulated digestive fluids that covers the electrolyte 
and enzymatic requirements. This particular digestion protocol also has the flexibility 
for digestion specific investigation via the addition of specific bio-chemicals and 
enzymes.  
 
From the literature review, the gases primarily observed within the upper gut were CO2 
but not H2 with the primary reason cited as low bacteria populations were found within 
the SI. However, because of the presences of bacteria within the upper gut, CO2 and H2 
were gases of interest. Based on this, the gas sensors used within the digestion simulator 
were a non-dispersive infrared (NDIR) gas sensors for measuring CO2 due to high 
selectivity. The thermal conductivity calorimetric sensor was chosen for measuring H2 
because of its ability to work within anaerobic environments at ppm levels. Lastly, a 
liquid-electrolyte based electrochemical sensor for oxygen (O2) sensing was also used to 
ensure that the digestion simulation reactor was anaerobic throughout the simulation. 
Additional digestion simulation characterisations were also involved to observe food-
matrix breakdown and its link to gas production mechanisms. Additionally, 
characterisation methods to observe the bacterial metabolic by-products produced 
during the SI phase simulations were used as they are providing insight into bacterial 
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survival and fermentation activity which also greatly impacts on digestive health 
outcomes. 
  
  
48 
 
2.12  References 
[1] R. P. Arasaradnam, J. A. Covington, C. Harmston, and C. U. Nwokolo, "Review 
article: next generation diagnostic modalities in gastroenterology--gas phase volatile 
compound biomarker detection," Aliment Pharmacol Ther, vol. 39, no. 8, pp. 780-9, 
Apr 2014. 
[2] L. Pauling, A. B. Robinson, R. Teranishi, and P. Cary, "Quantitative analysis of 
urine vapor and breath by gas-liquid partition chromatography," Proc Natl Acad Sci 
USA, vol. 68, no. 10, pp. 2374-2376, 1971. 
[3] K. Kalantar-Zadeh, N. Ha, J. Z. Ou, and K. J. Berean, "Ingestible Sensors," ACS 
Sens vol. 2, no. 4, pp. 468-483, Apr 28 2017. 
[4] J. S. Cornes, "Number, size, and distribution of Peyer's patches in the human 
small intestine: Part I The development of Peyer's patches," Gut, vol. 6, no. 3, pp. 225-
9, Jun 1965. 
[5] H. Gray, Anatomy of the human body. Lea & Febiger, 1878. 
[6] J. M. Sanchez and R. D. Sacks, "GC analysis of human breath with a series-
coupled column ensemble and a multibed sorption trap," Anal Chem, vol. 75, no. 10, pp. 
2231-2236, 2003. 
[7] M. D. Levitt, "Intestinal gas," in Modern Concepts in Gastroenterology, vol. 2, 
Springer, Ed. Boston, 1989, pp. 279-289. 
[8] M. D. Levitt and J. H. J. Bond, "Volume, composition, and source of intestinal 
gas," Gastroenterol, vol. 59, no. 6, pp. 921-9, Dec 1970. 
[9] H. K. Kuramitsu, X. He, R. Lux, M. H. Anderson, and W. Shi, "Interspecies 
interactions within oral microbial communities," Microbiol Mol Biol Rev, vol. 71, no. 4, 
pp. 653-70, Dec 2007. 
  
49 
 
[10] M. D. Levitt, "Volume and composition of human intestinal gas determined by 
means of an intestinal washout technic," N Engl J Med, vol. 284, no. 25, pp. 1394-8, Jun 
24 1971. 
[11] A. Allen and G. Flemstrom, "Gastroduodenal mucus bicarbonate barrier: 
protection against acid and pepsin," Am J Physiol Cell Physiol, vol. 288, no. 1, pp. C1-
19, Jan 2005. 
[12] P. B. Mensink, R. H. Geelkerken, A. B. Huisman, E. J. Kuipers, and J. J. 
Kolkman, "Effect of various test meals on gastric and jejunal carbon dioxide: A study in 
healthy subjects," Scand J Gastroenterol, vol. 41, no. 11, pp. 1290-1298, Nov 2006. 
[13] C. J. Bettinger, "Materials advances for next-generation ingestible electronic 
medical devices," Trends Biotechnol, vol. 33, no. 10, pp. 575-585, Oct 2015. 
[14] M. D. Levitt, "Production and excretion of hydrogen gas in man," N Engl J Med, 
vol. 281, no. 3, pp. 122-7, Jul 17 1969. 
[15] C. Y. C. Yang, C. S.  
Chen, G. H. , "Small-intestinal bacterial overgrowth in patients with liver cirrhosis, 
diagnosed with glucose H2 or CH4 breath tests," Scand J Gastroenterol, vol. 33, no. 8, 
pp. 867-871, 2009. 
[16] D. C. Savage, "Microbial ecology of the gastrointestinal tract," Annu Rev 
Microbiol, vol. 31, pp. 107-133, 1977. 
[17] G. Korotcenkov, "Metal oxides for solid-state gas sensors: What determines our 
choice?," Mater Sci Eng B, vol. 139, no. 1, pp. 1-23, 2007. 
[18] D. Kohl, "Function and applications of gas sensors," J Phys D, vol. 34, no. 19, 
pp. R125-R149, 2001. 
  
50 
 
[19] J. Dewulf, H. Van Langenhove, and G. Wittmann, "Analysis of volatile organic 
compounds using gas chromatography," Trends Analyt Chem, vol. 21, no. 9-10, pp. 
637-646, 2002. 
[20] N. J. Dominy, "Adaptive function of soil consumption: an in vitro study 
modeling the human stomach and small intestine," J Exp Biol, vol. 207, no. 2, pp. 319-
324, 2004. 
[21] E. V. De Hoffmann, S., Mass spectrometry - principles and applications, 2 ed. 
Wiley, 2000. 
[22] D. Smith and P. Spanel, "Selected ion flow tube mass spectrometry (SIFT-MS) 
for on-line trace gas analysis," Mass Spectrom Rev, vol. 24, no. 5, pp. 661-700, Sep-Oct 
2005. 
[23] P. Werle, F. Slemr, K. Maurer, R. Kormann, R. Mücke, and B. Jänker, "Near- 
and mid-infrared laser-optical sensors for gas analysis," Opt Lasers Eng, vol. 37, no. 2-
3, pp. 101-114, 2002. 
[24] J. Hodgkinson and R. P. Tatam, "Optical gas sensing: a review," Meas Sci 
Technol, vol. 24, no. 1, 2013. 
[25] C. McDonagh, C. S. Burke, and B. D. MacCraith, "Optical chemical sensors," 
Chem Rev, vol. 108, no. 2, pp. 400-22, Feb 2008. 
[26] J. Z. Ou, C. K. Yao, A. Rotbart, J. G. Muir, P. R. Gibson, and K. Kalantar-
zadeh, "Human intestinal gas measurement systems: in vitro fermentation and gas 
capsules," Trends Biotechnol, vol. 33, no. 4, pp. 208-13, Apr 2015. 
[27] K. Arshak, E. Moore, G. M. Lyons, J. Harris, and S. Clifford, "A review of gas 
sensors employed in electronic nose applications," Sensor Review, vol. 24, no. 2, pp. 
181-198, 2004. 
  
51 
 
[28] V. Bellon-Maurel, O. Orliac, and P. Christen, "Sensors and measurements in 
solid state fermentation: a review," Process Biochem, vol. 38, no. 6, pp. 881-896, 2003. 
[29] A. Pavlou, A. P. F. Turner, and N. Magan, "Recognition of anaerobic bacterial 
isolates in vitro using electronic nose technology," Lett Appl Microbiol, vol. 35, no. 5, 
pp. 366-369, 2002. 
[30] H. Segawa, E. Ohnishi, Y. Arai, and K. Yoshida, "Sensitivity of fiber-optic 
carbon dioxide sensors utilizing indicator dye," Sens Actuators B Chem, vol. 94, no. 3, 
pp. 276-281, 2003. 
[31] M. A. Butler, "Optical fiber hydrogen sensor," Appl Phys Lett, vol. 45, no. 10, 
pp. 1007-1009, 1984. 
[32] Z. Zhang, H. Jiang, Z. Xing, and X. Zhang, "A highly selective 
chemiluminescent H2S sensor," Sens Actuators B Chem, vol. 102, no. 1, pp. 155-161, 
2004. 
[33] J. Hodgkinson and R. P. Tatam, "Optical gas sensing: a review," Meas Sci 
Technol, vol. 24, no. 1, pp. 1 - 59, 2013. 
[34] P. Jasinski, "Solid-state electrochemical gas sensors," (in English), Material 
Science-Poland, vol. 24, no. 1, pp. 269-278, 2006. 
[35] J. R. Stetter and J. Li, "Amperometric gas sensors - a review," Chem Rev vol. 
108, no. 2, pp. 352-66, Feb 2008. 
[36] X. Zhang, H. Ju, and J. Wang, Electrochemical sensors, biosensors and their 
biomedical applications. Academic Press., 2011. 
[37] N. H. Park, T. Akamatsu, T. Itoh, N. Izu, and W. Shin, "Calorimetric 
thermoelectric gas sensor for the detection of hydrogen, methane and mixed gases," 
Sensors, vol. 14, no. 5, pp. 8350-8362, May 9 2014. 
  
52 
 
[38] M. S. Silberberg, Principles of general chemistry. New York: McGraw-Hill 
Higher Education, 2007. 
[39] A. Rotbart, P. J. Moate, C. K. Yao, J. Z. Ou, and K. Kalantar-Zadeh, "A novel 
mathematical model for the dynamic assessment of gas composition and production in 
closed or vented fermentation systems," Sens Actuators B Chem, vol. 254, pp. 354-362, 
2018. 
[40] F. J. Ingelfinger and W. O. Abbott, "Intubation studies of the human small 
intestine," Dig Dis Sci vol. 7, no. 11, pp. 468-474, 1940. 
[41] S. Maqbool, H. P. Parkman, and F. K. Friedenberg, "Wireless capsule motility: 
comparison of the SmartPill GI monitoring system with scintigraphy for measuring 
whole gut transit," Dig Dis Sci, vol. 54, no. 10, pp. 2167-2174, Oct 2009. 
[42] J. L. Fidler, L. Guimaraes, and D. M. Einstein, "MR imaging of the small 
bowel," Radiographics, vol. 29, no. 6, pp. 1811-25, Oct 2009. 
[43] K. A. Kelly, "Gastric emptying of liquids and solids: roles of proximal and distal 
stomach," Am J Physiol, vol. 239, no. 2, pp. G71-6, Aug 1980. 
[44] A. G. Oomen, C. J. Rompelberg, M. A. Bruil, C. J. Dobbe, D. P. Pereboom, and 
A. J. Sips, "Development of an in vitro digestion model for estimating the 
bioaccessibility of soil contaminants," Archives of Environmental Contamination and 
Toxicology, vol. 44, no. 3, pp. 281-7, Apr 2003. 
[45] M. Minekus et al., "A standardised static in vitro digestion method suitable for 
food - an international consensus," Food Funct, vol. 5, no. 6, pp. 1113-24, Jun 2014. 
[46] E. Fernandez-Garcia, I. Carvajal-Lerida, and A. Perez-Galvez, "In vitro 
bioaccessibility assessment as a prediction tool of nutritional efficiency," Nutr Res, vol. 
29, no. 11, pp. 751-760, Nov 2009. 
  
53 
 
[47] E. Nicolaides, E. Galia, C. Efthymiopoulos, J. B. Dressman, and C. Reppas, 
"Forecasting the in vivo performance of four low solubility drugs from their in vitro 
dissolution data," Pharm Res, vol. 16, no. 12, pp. 1876-1882, 1999. 
[48] C. W. Pouton, "Formulation of poorly water-soluble drugs for oral 
administration: physicochemical and physiological issues and the lipid formulation 
classification system," Eur J Pharm Sci, vol. 29, no. 3-4, pp. 278-287, Nov 2006. 
[49] A. G. Oomen et al., "Comparison of five in-vitro digestion models to study the 
bioaccessibility of soil contaminants," Environ  Sci Technol, vol. 36, no. 15, pp. 3326-
3334, 2002. 
[50] J. W. Woolnough, J. A. Monro, C. S. Brennan, and A. R. Bird, "Simulating 
human carbohydrate digestionin vitro: a review of methods and the need for 
standardisation," J Food Sci Technol, vol. 43, no. 12, pp. 2245-2256, 2008. 
[51] M. Minekus et al., "A standardised static in vitro digestion method suitable for 
food - an international consensus," Food & Function, vol. 5, no. 6, pp. 1113-24, Jun 
2014. 
[52] D. F. Evans, G. Pye, R. Bramley, A. G. Clark, T. J. Dyson, and J. D. Hardcastle, 
"Measurement of gastrointestinal pH profiles in normal ambulant human subjects," Gut, 
vol. 29, no. 8, pp. 1035-1041, 1988. 
[53] C. A. Lozupone, J. I. Stombaugh, J. I. Gordon, J. K. Jansson, and R. Knight, 
"Diversity, stability and resilience of the human gut microbiota," Nature, vol. 489, no. 
7415, pp. 220-30, Sep 13 2012. 
[54] M. Kleerebezem and E. E. Vaughan, "Probiotic and gut lactobacilli and 
bifidobacteria: molecular approaches to study diversity and activity," Annual Review of 
Microbiology, vol. 63, pp. 269-90, 2009. 
  
54 
 
[55] W. H. Holzapfel, P. Haberer, J. Snel, U. Schillinger, and J. H. Huis in't Veld, 
"Overview of gut flora and probiotics," International Journal of Food Microbiology, 
vol. 41, no. 2, pp. 85-101, May 26 1998. 
[56] P. Fayolle, D. Picque, and G. Corrieu, "Monitoring of fermentation processes 
producing lactic acid bacteria by mid-infrared spectroscopy," Vib Spectrosc, vol. 14, no. 
2, pp. 247-252, 1997. 
[57] R. M. El-Abassy, P. J. Eravuchira, P. Donfack, B. von der Kammer, and A. 
Materny, "Fast determination of milk fat content using Raman spectroscopy," Vib 
Spectrosc, vol. 56, no. 1, pp. 3-8, 2011. 
[58] E. B. Hanlon et al., "Prospects for in-vivo Raman spectroscopy," Phys Med 
Biol., vol. 45, no. 2, pp. R1-R59, 2000. 
[59] N. P. Shah, "Probiotic bacteria: selective enumeration and survival in dairy 
foods," J Dairy Sci, vol. 83, no. 4, pp. 894-907, 2000. 
[60] K. Kailasapathy and J. Chin, "Survival and therapeutic potential of probiotic 
organisms with reference to Lactobacillus acidophilus and Bifidobacterium spp," 
Immunol Cell Biol, vol. 78, no. 1, pp. 80-8, Feb 2000. 
[61] A. Bezkorovainy, "Probiotics: determinants of survival and growth in the gut," 
Am J Clin Nutr, vol. 73, no. 2 Suppl, pp. 399S-405S, Feb 2001. 
[62] D. Monleon, J. M. Morales, A. Barrasa, J. A. Lopez, C. Vazquez, and B. Celda, 
"Metabolite profiling of fecal water extracts from human colorectal cancer," NMR 
Biomed, vol. 22, no. 3, pp. 342-8, Apr 2009. 
[63] P. Marteau, M. Minekus, R. Havenaar, and J. H. J. Huis In’t Veld, "Survival of 
lactic acid bacteria in a dynamic model of the stomach and small intestine: validation 
and the effects of bile," J Dairy Sci, vol. 80, no. 6, pp. 1031-1037, 1997. 
  
55 
 
[64] E. Pyleris, E. J. Giamarellos-Bourboulis, D. Tzivras, V. Koussoulas, C. 
Barbatzas, and M. Pimentel, "The prevalence of overgrowth by aerobic bacteria in the 
small intestine by small bowel culture: relationship with irritable bowel syndrome," Dig 
Dis Sci, vol. 57, no. 5, pp. 1321-9, May 2012. 
[65] J. M. S. Dixon, "The fate of bacteria in the small intestine," J Pathol Bacteriol, 
vol. 79, no. 1, pp. 131-140, 1960. 
[66] D. S. Wishart et al., "HMDB 3.0--The Human Metabolome Database in 2013," 
Nucleic Acids Research, vol. 41, no. Database issue, pp. D801-7, Jan 2013. 
 
  
56 
 
Chapter 3 - Evaluation of developed in-vitro digestion 
simulator 
3.1  Introduction  
In chapter 1, the candidate outlines the need for the development of a novel in-vitro 
digestion system for the upper gut with the primary aim of broadening the current 
understanding of gas production and the impact that present bacteria have on gas 
production. The use of gases within the gut has been recognised as a biomarker for 
investigating, assessing, and diagnosis of gut health. A brief history of the use of gases 
as biomarkers for health was outlined, starting with the use of smell of large aromatic 
molecules emitted from sick patients [1]. With the increase in technology, key volatile 
organic compounds profiles were identified via breath and urine samples [2]. More 
recently, the ability to sense gas production within the gut has been advanced via 
swallowable gas sensing capsule [3]. However, in-vivo experimentation has many 
requirements that results in long delays, potentially risky to patients, and large financial 
costs. Further still, in-vivo experimentation struggles to explain the large variance in 
datasets which is typically a result of specific digestive functionality within the gut.  
 
In the previous chapter, the author’s in-vitro digestion simulator equipment and 
simulation protocols choices were outlined. Some of the main considerations that drove 
the design choices were having high-sample rate gas measurements, maintain a 
relatively low-cost set-up, ensure that no specialised training is required for the 
operation of the system, and to enable a high-throughput allowing for rapid validation. 
With the base design of the simulator decided, this chapter evaluates some of the design 
and protocol choices of the novel in-vitro digestion system. The author looks to do this 
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by using three well-studied model carbohydrates. The aim of this was to investigate the 
capabilities and potential problems due to equipment, protocol, and processes involved 
in the in-vitro simulations. The model carbohydrates used for the evaluation of the in-
vitro digestion system are glucose, fructose, and long-chain fructo-oligosaccharide 
called inulin [4]. To help assess the effectiveness of the in-vitro digestion simulations, a 
variety of characterisations were used including bacterial counting, SCFA analysis 
using NMR, and Raman spectroscopy. The outcomes of the in-vitro digestion 
evaluation were successful in that, the digestive outcomes were aligned with the current 
literature although improvements were sighted, particularly with the H2 measurements.    
 
3.2  Experiment method and materials 
3.2.1 Materials  
All materials used in the in-vitro digestion simulation were of technical grade and 
purchased from Sigma Aldrich, excluding the digestion enzymes. Amylase (38000 
U/mg), pepsin (10000 U/mg), and pancreatin (USP×1) were purchased from Southern 
Biological (Australia). The bacteria model used within this simulation was discussed in 
section - 2.9.3.1 Use of bacteria in the SI phase.   
 
3.2.2  In-vitro simulation  
The in-vitro simulations were carried out using a three-phase digestion process 
involving the oral phase, gastric phase, and the small intestine phase (discussed in detail 
in section - 2.9 Simulation protocol). Gas profiles and pH data were recorded at the rate 
of one sample per second across the entire digestion simulation. Glucose, fructose and 
inulin were added as the model carbohydrate during the simulations and were performed 
with and without bacterial inoculum in the small intestine phase (as explained below). 
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Simulations were repeated three times each (n=3). The preparation of bacteria 
inoculum, experiment setup, ingredients of simulated digestive fluids are described in 
section - 2.8 Simulated digestive fluids.  
 
3.2.2.1  Use of bacteria in the small intestine phase 
Digestion simulations that incorporated bacteria were added to the small intestine phase. 
The bacterial inoculum was stored at 5 C and removed 2 hours prior to end of the 
gastric phase to warm in the incubator/shaker (37 C). This was carried out to 
compensate for the bacterial lag phase. The volume of inoculum used was calculated 
based on the bacterial population specified on the probiotics product, resulting in 
approximately 106 CFU to simulate an average representation of jejunum and ilium 
phases. This is intermediate between the levels found in the jejunum (104 - 106 
CFU/mL) and proximal ileum (107 - 109 CFU/mL) [5]. 
 
3.2.2.2  Bacterial growth assay 
Bacterial population size was determined using the Gram stain procedure (Gram 
staining kit, Product number 77730-1KT-F, Sigma Aldrich) and optical microscope 
(Nikon LV150N). The cell counts were obtained via image analysis software called 
ImageJ [6]. Using a 100× objective, 30 images per model carbohydrate - bacterial 
simulation was analysed using the ImageJ pre-processing functions [7, 8] and particle 
analysis to determine the bacterial population. 
 
3.3  Raman spectroscopy  
The Raman spectra was obtained were obtained using a Horiba Scientific LabRAM HR 
evolution Raman spectrometer with a 532 nm laser excitation wavelength. Acquisitions 
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were carried out with an 1800 lines per mm grating for 25 s with 5 averages using a 
100× objective. Raman scans were taken at the end of each digestion simulation to 
observe the chemical and bacterial products of the digestion process.  
 
3.4  Evaluation results 
The digestion simulation (oral, gastric and small intestine phases) conducted for three 
model carbohydrates of glucose, fructose and inulin. These simulations were completed 
in triplicate (n=3) without and with the addition of bacteria during the small intestine 
phase. CO2, H2 and pH were continuously measured during these periods. CO2 and H2 
profiles are presented in Figure 3.1. The pH measurements are shown in Figure 3.2. The 
other characterisations like bacteria count, NMR analysis and Raman spectroscopy 
analysis are shown in Figure 3.3, Figure 3.4, Figure 3.5 respectively. 
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3.4.1 Gas production profiles 
 
Figure 3.1 - CO2 (left) and H2 (right) production from three model carbohydrates; (a) glucose, (b) 
fructose, (c) inulin, and; (d) model carbohydrate source of gas production. The colours in the graph 
represent the different phases in the digestion simulation. White – oral phase; light grey – gastric phase; 
dark grey – SI phase. 
 
3.4.1.1  Oral phase  
During the oral phase the quantity of CO2 and H2 production were at the lower limit of 
detection for both sensors. This result was expected given the digestion protocol limits 
the time of the oral phase to 5 mins, not allowing for significant quantity of gas to be 
produced.  
 
3.4.1.2  Gastric phase 
Within this phase, the gas production was a result of both chemical and enzymatic 
reactions. Specifically, in this phase of the simulation, CO2 is produced through the 
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chemical interaction between the added HCl and the NaHCO3 present within the SSF of 
the oral digesta [9, 10].  
 
The volume of CO2 production observed in the inulin simulations was lower than that of 
glucose and fructose with gas production of 0.75, 1.1 and 1.05 mL, for inulin, glucose 
and fructose respectively. The reduced CO2 production is a result of HCl competition 
between the NaHCO3 and the inulin. The acid neutralisation reaction [11], which is 
shown in equation (1), is the chemical reaction between NaHCO3 and HCl which results 
in known CO2 production. 
 
 NaHCO3 + HCl ⇁ NaCl + CO2 + H2O (1) 
 
The other chemical interaction that reduces the HCl concentrations within the gastric 
phase was the hydrolysis of inulin. The low pH within the gastric phase encourages the 
long fructooligo-chains within the inulin molecules to break, forming shorter 
fructooligo-complexes [12, 13]. The gastric pH of both inulin simulations showed an 
increased pH during the gastric phase that was slightly above the target pH (Figure 
3.2b). The breakdown of the long fructooligo chains (that make up inulin) was also 
confirmed by the Raman spectroscopy, which is discussed in section - 3.4.4.2 Chemical 
composition through Raman spectroscopy. 
Within the gastric phase of digestion simulations there was H2 gas that was produced 
for all of the three model carbohydrates. On average, glucose and inulin produced more 
H2 gas than the fructose samples. However, H2 production during the gastric phase was 
low for all three carbohydrates (0.05 to 0.10 mL). This quantity of H2 produced was 
approximately an order of magnitude less than CO2 production which is low but within 
the noise limit of the measurement system.  
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3.4.1.3  Small intestine phase 
Upon completion of the 2 h gastric phase, the addition of SIF was added to the in-vitro 
digestion simulator. With the injection of the SIF into the digestion simulation, a more 
neutral digesta pH was obtained. The high concentration of NaHCO3 in the SIF reacts 
with HCl content in the gastric digesta resulting in larger quantities of CO2 production.  
 
3.4.1.4  Small intestine – non-bacteria simulation 
In non-bacteria digestion simulations the CO2 production was greatest for the fructose 
simulation with a cumulative end-of-phase production of 5.97 mL (Figure 3.1b). This is 
an order of magnitude more than glucose (0.59 mL; Figure 3.1a), while the inulin 
simulation produces an intermediate level of CO2 (1.94 mL; Figure 3.1c).  
 
Injection of the SIF into the simulation increases the pH which reduces pepsin activity 
[14]. In the small intestine, pancreatin dominates the enzymatic reactions, but does not 
affect the model carbohydrates as they either are monomers (glucose and fructose) or 
have glucosidic bonds (inulin) that pancreatic amylase enzymes cannot cleave. As such, 
CO2 production is not associated with its presence. 
 
3.4.1.5  Small intestine – with bacteria 
For the simulations that investigated the impacts of bacteria on the gas production, the 
inoculum was added after the SIF. The change of pH to near neutral helps the activated 
bacteria survive the transit into the fermentation reactor. The small intestine simulations 
are run with bacteria to investigate the impact it has on gas production. It is important to 
re-affirm that the bacteria used in the digestion simulations are both homofermentative 
in nature and are not metabolically capable of producing CO2 [15, 16]. Despite this, 
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resultant CO2 measured in the headspace during simulations containing bacteria varied 
depending on the model carbohydrate under digestion. Lower quantities of CO2 
occurred for fructose (1.08 mL; Figure 3.1b) and glucose (1.85 mL; Figure 3.1a). 
However, the cumulative CO2 levels within the inulin simulation extrapolates to nearly 
10.0 mL (Figure 3.1c). Due to the small quantities of simulated digesta, the sensor for 
measuring CO2 was set to a lowest limit (5 %vol) to increase the accuracy of 
measurements but was quickly saturated in the SI phase. This can be seen in Figure 
3.1c. Inulin is a known fermentable carbohydrate that produces CO2 as it is 
enzymatically broken down via bacterial interaction [17]. 
 
To better observe the impact of the bacteria on the gas production, Figure 3.1d shows 
the difference in CO2 production between non-bacterial and bacterial simulations. As 
can be seen for the inulin simulations, nearly 60% (3 mL) of the gas generated was 
simply due to the presences of the bacteria being within the SI digesta. The CO2 
generated in the glucose simulations showed a slightly lesser impact of 40% (0.84 mL) 
with the addition of bacteria. Both glucose and inulin carbohydrate simulations showed 
positive increases in Figure 3.1d indicating that the presences of bacteria promoted 
additional gas into the in-vitro digestion simulator headspace. However, the production 
of CO2 for the fructose simulation after the addition of the bacteria, shows a large 
negative swinge of 70% (3.5 mL). This indicates that the presence of bacteria decreased 
the production of the CO2 into the headspace. The pH data for the bacterial fructose 
simulations shows a relatively flat profile compared to the non-bacterial fructose 
simulation. This would suggest that the presences of bacteria inhibit the CO2 producing 
chemical reactions that occurs within the non-bacterial fructose simulations.  
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3.4.2  Digestion simulation pH results  
The target pH of the oral, gastric, and small intestine phases is adjusted to pH 7.0, 3.0, 
and 7.0, respectively (which is discussed in section - 2.9 Simulation protocol). To 
observe any potential pH effects introduced by the model carbohydrates, a small 
window of 10% of the target pH was allowed before pH modifying solutions are added. 
The size of the pH window was based on in-vivo observations by Evans et al. [18]. 
 
 
Figure 3.2 - pH data for (a) all three phases of the digestion simulation; (b) the gastric phase; (c) the small intestine 
phase. The colours represent the phase of the simulation: White - oral phase; Light grey - gastric phase; Dark grey - 
small intestine phase 
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3.4.2.1  Gastric phase 
The pH through the gastric phase of glucose and fructose carbohydrates was relatively 
stable. This result was expected as both these carbohydrates are in their mono-form and 
will not interact with the HCl in the gastric digesta.  
 
The pH of the gastric phase in the inulin experiment is higher than the other two model 
carbohydrates. As previously mentioned (section 3.4.1.2 Gastric phase), inulin starts to 
hydrolyse within the acidic environment thus slightly reducing the acidity within the 
gastric digesta.  
 
3.4.2.2  Small intestinal phase 
Within the small intestine phase of the experiment, the pH is relatively stable and 
without much change from start to finish with one minor exception. A larger than 
expected pH increase was observed within the fructose non-bacteria simulations. It is 
likely that this gradual pH increase could be the result of the Maillard reaction slowly 
reducing fructose [19]. A requirement for the Maillard reaction is the presents of amino 
acids which can be found within the SI digesta via small quantities of decomposed 
amylase that has been denatured and enzymatically cleaved within the gastric phase 
[20]. However, the presents of the bacteria greatly slowed this process as they also 
consume the amino acids for their growth. Also, the bacteria’s surface contains main 
functional groups on its surface and as such, adsorption of amino acids onto its surface 
reducing the available amino acids for the reaction [21].  
 
3.4.3  Bacterial count  
The bacterial count was conducted to observe to evaluate the impact that the simulated 
model carbohydrate digestion had on their survivability. Typically, large bacterial 
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growths are good indicator of large fermentation output [22]. The bacterial population 
of the inoculum and the end digesta from the model carbohydrate bacterial simulations 
are counted using Gram staining and optical microscopy. Both the glucose and inulin 
experiments demonstrate a similar magnitude of bacterial growth with the glucose 
showing the largest overall increase. Contrary to this result, the inulin digestion 
simulation showed the highest gas production output out of the three model 
carbohydrates. This suggests that the bacteria produce additional by-products – 
including more gas production – with more complex food structures. Such an outcome 
was aligned with the current literature observations [23-25].  
 
 
Figure 3.3 -Bacterial growth due to model carbohydrates within the bacterial digestion simulations 
 
3.4.4  NMR and Raman analysis 
Raman spectroscopy and nuclear magnetic resonance (NMR) assessments were 
employed for analysing the short chain fatty acid (SCFA) and chemical constituents 
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within the digesta after the completion of the simulation experiments both with and 
without bacteria. 
 
3.4.4.1  Metabolomic study through NMR 
The NMR analysis from the completed digesta containing the protocol standard quantity 
(section - 2.10 Additional characterisations) of model carbohydrate at the outset showed 
very high amounts of undigested carbohydrate upon completion along with minor 
amounts of SCFAs. The SCFAs were present but in such low concentration that they 
were not able to be resolved from the baseline noise. As such, their quantities and 
identities could not be determined.  
 
To reduce the interference and masking of the SCFA by the remaining carbohydrate, a 
digestion simulation consisting of a lower concentration (one tenth of the standard 
quantity of carbohydrates) carbohydrate aliquot was introduced at the beginning of the 
experiment. The low concentration samples appeared to detect a greater amount of 
SCFAs compared to the standard digesta samples which could be due to the increased 
signal-to-noise ratio resulting from lower undigested carbohydrates within the sample. 
Figure 3.4 shows expansions of the proton NMR spectra for the three carbohydrate 
samples. The dotted line represents two of the major bacterial by-products which are 
lactic acid(1.31 / 1.324 ppm [26]) and the acetic acid (1.91 ppm [26]). Lactic acid in 
particular, is the primary by-product of the SBM fermentation processes and was 
anticipated to be clearly identified.  
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Figure 3.4 - Proton NMR spectra for standard digesta samples and low carbohydrate digesta samples 
 
Unfortunately, lactic acid and the majority of the SCFAs are produced in too low 
amount to be clearly resolved for identification purposes. The low concentration glucose 
sample showed the presence of a strong signal; however, it could not be positively 
matched to the SCFA’s or chemicals listed within the simulated digestive fluids.  
 
3.4.4.2  Chemical composition through Raman spectroscopy 
3.4.4.2.1  Glucose  
The Raman spectra of the glucose digestion simulation samples show an increase in the 
region of 1250 – 1750 cm-1 for the bacterial simulation. This can be attributed to the 
presence of large organics generated from the bacteria during the digestion simulation 
which is in agreement with the gas fermentation outcomes [27]. The two prominent 
peaks in the area of 3000 – 3500 cm-1 are associated with the protonation of OH- 
functional group [28]. 
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Figure 3.5 - Raman spectra for bacterial and no-bacteria digestion simulations 
 
 
3.4.4.2.2  Fructose  
For both non-bacteria and bacterial fructose Raman spectra, the increase in the intensity 
of the two OH- protonation peaks in the 3000 – 3500 cm-1 range [28] is much less than 
the glucose simulations. This could be associated with increased protons interacting 
NaHCO3 at the SI phase of digestion.  
 
3.4.4.2.3  Inulin 
Inulin is an aliphatic chain made of n-fructose like structures. Consequently, the 
intensity at 480 cm-1 reflects concentration of inulin left at the end of the chemical 
digestion simulation. With the bacterial digestion simulation, this peak drops in 
intensity reflecting signs of bacterial consumption of inulin. 
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3.5   In-vitro digestion simulation considerations and 
limitations 
Our developed novel in-vitro digestion simulation was successful in measuring CO2 and 
H2 gases produced through the upper digestion simulation.  The gastric and small 
intestine phases gave insight into the gas production sources, which were either 
chemical or bacterial in nature. Current in-vitro digestion simulations that use long 
sampling periods or one-time gas measurements miss such information present within 
the short-term gas dynamics. 
 
Glucose, inulin, and fructose within the gastric phase showed relatively similar CO2 and 
H2 production rates productions. Also, through short-term dynamic gas measurements, 
unique carbohydrate specific features were observed in the gas profiles when the 
digestion simulations transitioned into the small intestine phase. 
 
Inulin showed the largest CO2 and H2 gas production out of the three model 
carbohydrates due to the bacterial fermentation that was expected from a prebiotic 
oligosaccharide. In comparison, fructose only showed large CO2 production when no 
bacteria were present, which was attributed to the lack of efficient protonation by 
fructose. This also resulted in the reduced proliferation of the bacteria. In contrast, the 
bacteria reduced the CO2 production in the presence of fructose.  
 
3.5.1 Large variants in gas production measurements 
The sensors used within the in-vitro digestion simulations were not able to reliably 
measure H2 production. Large variances were observed in the H2 measurements 
indicating production were on the lower limit of detection for the H2 gas sensor 
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(observed through large error bars). This problem manifested within the gastric phase as 
it reflected higher end-of-phase production for the bacterial carbohydrate simulations 
compared to their non-bacterial carbohydrate simulations. The non-bacterial and 
bacterial simulations in the oral and gastric phase have the same chemical and 
enzymatic content which implies that the end-of-phase H2 production should be very 
similar, if not the same, production of H2. Additionally, the CO2 measurements saturated 
within the inulin bacterial digestion simulation but was adequate for the glucose and 
fructose simulations. Both problems are a result of small digesta quantities under 
simulation.  
 
As a possible improvement to the current in-vitro digestion setup, the quantities of food 
under simulation could be increased. It is important to note that balancing the quantity 
of digesta under simulation with enough headspace to allow for the pressure transducer 
to adequately maintain pressure. Too much digesta in the in-vitro simulator will over 
pressure the unit, dissolving more gas within the solution. Too little digesta and the 
quantity of gas produced from the simulation becomes difficult for the sensors to 
accurately measure.   
 
3.5.2 The duration of the SI phase 
The duration of the SI phase was suggested by Minekus et al.[29] to be 2 hours in 
duration but is too short to fully observe the impact that bacteria has on gas production. 
The H2 gas production profiles show signs of increasing production but is cut short by 
this limited duration. The durations of each phase were a recommendation given by 
Minekus et al. [29] but carefully advises about the macronutrient’s effects and 
individual (persons) variability on digestion transit times. Other studies have seen that 
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small intestine transit times can vary up to 5 hours and potentially longer [30]. As such, 
increasing the transit time within the small intestine phase is still physiologically sound 
and provides the means to better understand the impact of bacterial growth and gas 
production in small intestine phase digestion. 
 
3.6   Conclusions 
This work presents the development and successful assessment of the author’s real-time 
gas monitoring in-vitro digestion system. The real-time gas production profiles and pH 
provide a unique perspective allowing the observation of when and how-much is being 
produced rather than just a single quantitative measurement. Further still, this system 
was able to demonstrate the importance of bacteria present within the simulations as the 
difference in gas production is vastly different. 
 
The Raman spectroscopy characterisations helped provide information about the 
breakdown of food stimulus and additional digesta constituents throughout the digestion 
simulation phases. The NMR analysis struggled to quantify or identify any SCFA’s 
within the digesta samples. Ultimately, the Raman and NMR analysis could not provide 
anything conclusive due to the very small analyte quantity presented within the digesta 
samples. 
 
The evaluation of the in-vitro digestion system demonstrated a working simulator 
whose outcomes are aligned with past and current literature and clinical data. However, 
there are several improvements that can be made to the system including increasing the 
quantity of food stimulus/digesta through the unit to increase the amount of gas 
generated within the simulations. The other major suggestion was to extend the SI phase 
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duration allowing the bacteria more time to better observe their impact. Such 
improvements will greatly enhance the sensitivity, digestive information, and overall 
temporal gas production profile information obtainable. 
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Chapter 4 - An in-vitro upper gut simulator for assessing 
continuous gas production: a proof-of-concept using 
milk digestion 
4.1  Introduction  
In chapter 3, the author’s in-vitro digestion simulator was evaluated with three model 
carbohydrate to assess the if the digestive outcomes from the simulator were aligned 
with the currently available literature. The digestive outcomes were assessed based on 
the several characterisations including real-time CO2 and H2 gas production profiles, 
real-time pH profiles, bacteria count comparison, Raman and NMR analysis. The results 
from the evaluation were in good agreement with literature but demonstrated several 
key aspects needed to improve the gas sensing capacity. 
 
In this chapter, the author outlines the improvements made on the in-vitro digestion 
system and demonstrates via proof-of-concept that it can be used as a potential 
diagnostic tool for upper gut gas production analysis. The food-type chosen for this 
proof-of-concept was bovine milk (which will be referred to as milk) as it rich in 
macronutrients, commonly consumed as part of a normal diet [1] and has been well 
documented due to gut disorders such as lactose intolerance. Where numerous gas 
related symptoms, such as bloating and flatulence, have been commonly observed in 
lactose intolerance patients [2-6]. The digestive outcomes, including the gas production 
outcomes, align with clinical observations with simulations regarding the impact of 
lactase and ‘healthy’ bacterial concentration (106 CFU). Digestion scenarios involving 
the absences of lactase (i.e. lactose intolerant) and increased bacterial concentrations 
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(109 CFU) was also investigated with favourable outcomes that are in good agreement 
with the current literature. 
 
The content of this chapter was published as a fully reviewed paper in the journal 
“Functional Foods” [7]. 
 
4.2  In-vitro digestion simulation improvements to suit the 
needs as a potential diagnostic tool 
In the previous chapter, the author outlined and evaluated the developed real-time gas 
monitoring in-vitro digestion system. The outcomes of the model carbohydrate 
simulations were promising, demonstrating digestive outcomes that aligned with the 
current literature. However, two significant limitations were apparent after the 
evaluation with few improvements required to increase the simulator’s capabilities – 
improving the H2 sensor measurement precision, and; the extension of the SI phase 
duration to better investigate the impact of bacteria on the SI digestion phase. 
 
In order to more reliably interpret outcomes based on the H2 measurements within the 
in-vitro digestion system, the sensor’s operational functionality was investigated to 
improve its performance. The current H2 sensor is a thermal conductive device (TCD) 
based sensor capable of linearly measurements up to ~60% LEL (lower explosive limit), 
which for H2 is ~2.4% concentration [8]. According to the sensor application notes, the 
sensor’s suggested operational temperature is between 400-500 °C at the sensing 
mechanism (the catalytic bead) when used within the recommended voltage range (3V – 
4.25V). [9, 10]. Lower catalytic bead operation temperatures result in an improved H2 
sensitivity with decreased cross-talk interference from other gases. 
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Due to the small bacterial concentrations found within the SI tract [11], the H2 sensor 
was configured to operate with higher H2 sensitivity. With this in mind, the driving 
circuit for the sensor was set to the lowest recommended voltage (3V, 135 mW). The 
assumption made for this configuration is that power delivered to the catalytic bead can 
maintain a constant temperature during the digestion simulation. Such a configuration 
decreases the measurement stability but increased the sensitivity.   
 
From the gas production profiles demonstrated from the simulations in the previous 
chapter (section - 3.4.1 Gas production profiles), the CO2 quantities (a non-combustible 
gas) measured in the digestion simulations were an order magnitude greater than H2. 
Although humidity was not directly measured, the temperature of the digestion 
simulations was operated at 37 °C, which greatly increases the humidity within the 
headspace. The H2 sensor’s response due to humidity was factored by allowing the 
heated bio-reactor containing the carbohydrate aliquot to equilibrate at the beginning of 
the experiment (section - 2.9 Simulation protocol). However, the large cross-talk gases 
in the headspace and small quantity of target gas present, it was likely that the large H2 
errors observed within the previous chapter (section - 3.4.1 Gas production profiles) 
were a result of the TCD sensor not being able to maintain the required temperature on 
the catalytic bead resulting in unpredictable H2 sensitivities. 
 
Based on this, the TCD sensor configuration was changed to a highest voltage (4.25V) 
to supply more power to the catalytic bead, helping it thermally recover faster and 
improving the sensor response stability. The disadvantage to this configuration is a loss 
in H2 sensitivity.  Results of the operational change in the H2 sensor can be seen in 
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section - 4.2 H2 gas measurements, showing significantly smaller error bars, particularly 
in the last digestive phase (the SI phase).  
 
The other action taken to help improve the H2 sensor’s measurements was to physically 
increase the quantity of gas constituents produced within the simulation. It is possible to 
take advantage of two aspects of the author’s in-vitro digestion simulator – the digestion 
protocol’s scalability [12] and the limited headspace size of the digestion simulation 
equipment. It is important to note that increasing the quantities of overall digestion 
simulation constituents will also increase the cross-talk gasses (except humidity). This 
result is acceptable as the current TCD able to maintain a consistent and repeatable 
cross-talk response so that it can be calculated out of the TCD’s response. The scaling 
of the digestion protocol should be kept within the bounds of what is physiologically 
relevant [12]. Based on this, a small increase in the food-stimulus was made increasing 
the starting food stimulus aliquot from 10 to 15 mL. As such, the simulated digestion 
fluid composition and quantities have been updated to reflect the increased food-
stimulus (Table 4.1, 4.2, and 4.3).   
 
Lastly, the extension of the duration of the SI phase is important to thoroughly 
investigate how the bacteria model impacts the gas production in the SI digestion phase. 
From the previous chapter, the 2 h SI duration recommended by Minekus et al. [12] was 
enough to explore the bacteria’s gas production impact on the acid-neutralisation 
reactions. The bio-relevance of this digestion function in the gut is imperative as it 
determines the fate of many bio-chemical and enzymatic reactions as well as bacteria 
survival and fermentation behaviour. Many people have studied bacteria survival rates 
through the gastric – SI passage [13, 14] but have not investigated their capacity to 
ferment foods after the acid-neutralisation process. As such, little is known about the 
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fate and effectiveness of the residing bacteria and their capacity to ferment foods within 
the SI. As such, the SI phase duration recommendations made by Minekus et al. [12] 
was based on a compromise of literature and clinical observations citing many food-
types and physiological factors can vastly modify the SI transit time. Such factors have 
also been mentioned in [15, 16]. As such, the SI phase duration was increased for the 
investigation, extending the SI phase duration to 4 h. 
 
In summary, the quantity and digestion phase timing modifications to the digestion 
protocol can be seen in Figure 4.1. Due to the increased quantity of food stimulus and 
simulated digestive fluids, the simulated digestive fluids composition quantities have 
been updated (Tables 4.1, 4.2, and 4.3).  
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Figure 4.1 - Modified digestion protocol – changes are showed in red. Food stimulus quantity, simulated 
digestion fluid quantities, and SI phase duration have been updated to reflect the new in-vitro digestion 
simulation protocol. 
 
  
Oral Phase – 
15 ml Simulated Saliva Fluid 
(SSF) 
Gastric Phase – 
30 ml Simulated Gastric Fluid 
(SGF) 
Small Intestine Phase – 
60 ml Simulated Gastric Fluid 
(SIF) 
5 minutes 
4 hours 
2 hours 
Food stimulus (15ml) 
Logged CO
2 H2 and pH gas data 
Digestion simulator units are purged 
with N2 
Added bacteria inoculum 
Target pH = 7.0 
Target pH = 3.0 
Target pH = 7.0 
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Table 4.1 - Modified list of chemicals used for SSF 
 Simulated saliva fluid (SSF) 
 Stock concentration pH 7.0 
Constituent g/l mol/l Volume (ml) Concentration 
(mmol/l) 
     
KCl 37.3 0.5 0.453 15.1 
KH2PO4 68 0.5 0.111 3.7 
NaHCO3 48 1 0.204 13.6 
NaCl 117 2 - - 
MgCl2(H2O)6 30.5 0.15 0.015 0.15 
(NH4)2CO3 48 0.5 0.0018 0.06 
CaCl2(H2O)2  44.1 0.3 0.015 1.5 
DI water   14.200  
     
For pH adjustment of the 
stock concentration 
 
HCl 
 
 6 0.018 1.1 
Addition of enzymes  (Per 15ml SSF) 
 U/mg  mg U  
Amylase 38000 - 
40000 
 0.0039 1140 -  
1200 
Pepsin 8000 - 
10000 
 - - 
*Lactase 1000-1200  
(per ml) 
   
     
Pancreatin 
(USPx1) 
    
Amylase activity 25 USP  - - 
Protease activity 25 USP  - - 
Lipase activity 2 USP  - - 
     
The concentrations, quantities used, and solution pH for the SSF. The volumes are 
calculated for a final volume of 15 ml. The digestive enzyme lactase is in liquid form. 
The table has been updated from section - 2.8 Simulated digestive fluids to reflect the 
quantity modification for the in-vitro digestion protocol. 
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Table 4.2 – Modified list of chemicals used for SGF.  
 Simulated gastric fluid (SGF) 
 Stock concentration pH 2.5 
Constituent g/l mol/l Volume (ml) Concentration 
(mmol/l) 
     
KCl 37.3 0.5 0.414 6.9 
KH2PO4 68 0.5 0.054 0.9 
NaHCO3 48 1 0.750 25.0 
NaCl 117 2 0.798 47.2 
MgCl2(H2O)6 30.5 0.15 0.024 0.1 
(NH4)2CO3 48 0.5 0.030 0.5 
CaCl2(H2O)2  44.1 0.3 0.0006 0.15 
DI water   28.019  
     
For pH adjustment of the 
stock concentration 
 
HCl 
 
 6 0.052 15.6 
Addition of enzymes  (Per 30ml SGF) 
 U/mg  mg U 
Amylase 38000 - 
40000 
 - - 
Pepsin 8000 - 10000  8 64000 - 
 80000 
*Lactase 1000-1200  
(per ml) 
   
     
Pancreatin 
(USPx1) 
    
Amylase 
activity 
25 USP  - - 
Protease 
activity 
25 USP  - - 
Lipase activity 2 USP  - - 
     
The concentrations, quantities used, and solution pH for the SGF. The volumes are 
calculated for a final volume of 30 ml. The digestive enzyme lactase is in liquid form. 
The table has been updated from section - 2.8 Simulated digestive fluids to reflect the 
quantity modification for the in-vitro digestion protocol. 
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Table 4.3 – Modified list of chemicals used for SIF.  
 Simulated intestinal fluid (SIF) 
 Stock concentration pH 8.2 
Constituent g/l mol/l Volume (ml) Concentration 
(mmol/l) 
     
KCl 37.3 0.5 0.816 6.8 
KH2PO4 68 0.5 0.096 0.8 
NaHCO3 48 1 5.100 85 
NaCl 117 2 1.152 38.4 
MgCl2(H2O)6 30.5 0.15 0.132 0.33 
(NH4)2CO3 48 0.5 - - 
CaCl2(H2O)2  44.1 0.3 0.0096 0.6 
DI water   52.694  
     
For pH adjustment of the 
stock concentration 
 
HCl 
 
 6 - - 
Addition of enzymes  (Per 60ml SIF) 
 U/mg  mg U 
Amylase 38000 - 40000  - - 
Pepsin 8000 - 10000  - - 
*Lactase 1000-1200  
(per ml) 
 0.525 (ml) 525 -  
630 
     
Pancreatin 
(USPx1) 
  320 USP U 
Amylase 
activity 
25 USP   8000 
Protease 
activity 
25 USP   8000 
Lipase 
activity 
2 USP   640 
     
The, concentrations, quantities used, and solution pH for the SIF. The volumes are 
calculated for a final volume of 60 ml. 15.625 mg/l of dried bovine bile was also added 
to incorporate 160 mM into the SIF. The digestive enzyme lactase is in liquid form. The 
table has been updated from section - 2.8 Simulated digestive fluids to reflect the 
quantity modification for the in-vitro digestion protocol 
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4.3  Materials and Methods 
4.3.1 Milk digestion experiment outline 
The in-vitro digestion simulations of milk are primarily looking at the alignment of 
digestive outcomes with the literature and clinical observations. The simulations also 
included a SBM and the digestive enzyme lactase. The digestive outcomes were 
assessed by several characterisations from the in-vitro digestion simulation which are: 
real-time CO2 and H2 gas production profiles and pH, bacterial counts comparisons, 
Raman spectrography, and NMR metabolomic analysis.  
 
The milk simulations were conducted across three conditions: standard digestion 
simulation (no bacteria present in the SI phase (non-bacterial)), milk digestion with 106 
CFU, and milk digestion with 109 CFU.  The presence of lactase enzymes on the gas 
production profiles and pH were also observed by repeating the three conditions 
previously mentioned with and without the presence of lactase enzymes in the SI phase. 
Each digestion simulation was repeated in triplicate (n=3). 
 
4.3.2 Simulation materials and updated protocol  
The materials used and where they were purchased can be found in section – chapter 2 – 
Method and materials. The updated digestion protocols and simulated digestion fluid 
quantities seen in Figure 4.1 and Table 4.1, 4.2, and 4.3 respectively. Milk used in the 
simulation was sourced from the local supermarket and stored at 4 °C until needed. The 
additional digestive enzyme Lactase (10000 U/mg) was purchase from Southern 
Biological (Australia).  
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4.3.2.1  Preparation of the bacterial inoculum 
The preparation of the bacterial inoculum was outlined in section - 2.9.3.1 Use of 
bacteria in the SI phase) 
 
4.3.2.2  Experiment setup, pressure testing and headspace purging 
phases  
Based on the modified digestion protocols previously mentioned, 15 mL of milk was 
directly injected into the digestion simulator unit within the agitating water bath and 
allowed to warm up to 37 °C for 20 min. The units were checked to see if they were 
hermetically sealed and then purged with N2 gas to produce an anaerobic environment 
(see section - 2.9 Simulation protocol). 
 
4.3.2.3  Oral phase 
Simulated saliva fluid (SSF) was prepared based of the method of Minekus et al. [12] 
(Table 4.1). A 15 mL aliquot of milk was placed in the digestion simulator to warm up 
to temperature. During the warm-up period, humidity also increases within the in-vitro 
digestion simulator unit allowing the H2 sensor to establish its new baseline 
measurement. This forms the reference point for the H2 measurements. The digestion 
simulation started with the injection of 15 mL of SSF into the unit, which was incubated 
at 37 °C for 5 min with an agitation speed of 0.5 rpm. 
 
4.3.2.4  Gastric phase 
Simulated gastric fluid (SGF) used in the gastric phase was also prepared based the 
method of Minekus et al. [12] (Table 4.2), with the following modification to pH. Since 
the gastric phase directly continues from the oral phase, the specific pH of the SGF 
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solution was modified to 2.5 such that, when added to the previous phase without any 
food stimulus, the resultant pH reached the target of 3.0.  
 
After the oral phase was complete, 30 mL of SGF was added to the digestion simulator 
unit and further incubated for 2 h. The target pH of the gastric phase was 3.0 and where 
required, 1 M HCl was added to adjust the pH.  
 
4.3.2.5  2.3.5 SI phase 
Simulated SI fluid (SIF) used in the SI phase was prepared using a modification of 
Minekus et al. [12] (Table 4.3). Keeping with the developed protocol, the pH of the SIF 
solution was set to 8.2. When combined with the constituents from preceding phases, 
without the influence of a food stimulus, a pH of 7.0 was produced.  
 
After completion of the gastric phase, 60 mL of SIF was injected into the digestion 
simulation giving a total volume of 120 ml. After this process, the resultant pH of the 
small intestine digesta was measured to be between 6.0 - 8.0. This range was seen to be 
reflective of the in-vivo conditions of the small intestine and allows the exploration of 
pH changes directly associated with food digestion [17]. Based on the protocol of 
Minekus et al. [12], pH adjustments were made with the addition of 1 M NaOH or 1 M 
HCl where required. The SI simulation was incubated at 37°C for a final 4 h.   
 
For digestion simulations that investigate the impact of bacteria – two concentrations of 
bacteria were explored. First a lower concentration of 106 CFU digestion simulations, 
this was implemented through the addition of 20 µL of inoculum which was added after 
the SIF. Secondly a higher concentration of 109 CFU digestion simulation was 
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implemented by the addition of 2 mL of inoculum and was added after the SIF was 
introduced into the digestion simulation unit. 
 
4.3.3 Raman spectroscopy  
Raman scans were taken at the end of each digestion simulation to observe changes in 
the milk due to chemical and bacterial effects of the digestion process. The Raman 
spectrum of milk digestion samples was obtained using a Horiba Scientific LabRAM 
HR evolution Raman spectrometer with a 532 nm laser excitation wavelength. 
Acquisitions were carried out with an 1800 lines per mm grating for 25 s with 5 
averages using a 100× objective.  
 
4.3.4 NMR metabolite analysis 
Nuclear magnetic resonance (NMR) spectra was acquired on a 500 MHz Agilent DD2 
NMR spectrometer at 25 °C, fitted with a 5 mm room temperature probe. A capillary 
containing D2O and TSP (3371 µmol/L) was placed inside the NMR tubes of the 
samples to provide a lock signal and reference. The PRESAT sequence (4-step 
PURGE), utilizing a presaturation delay of 2 s, was used to suppress the residual water 
signal. Each sample was acquired using 256 scans. The metabolites observed in the 
spectra were identified using the Human Metabolome Database [18]. 
 
4.3.5 Bacterial growth assay 
Dilutions of the milk digesta were plated using MRS agar (110660, Merck Millipore) 
via the pour plate method. Each plate was incubated for 48 h at 37 °C in anaerobic 
conditions (N2) and completed in triplicate with colonies counted by hand. 
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4.3.6 Data processing and statistical analysis 
Gas production data processing was conducted according to Rotbart et al. [19]. 
Software used for all filtering and data processing was completed using Matlab 2016B 
and OriginLabs 9.0 SR2. An one-way ANOVA analysis was completed using 
OriginLabs 9.0 SR2 on all CO2 and H2 gas profiles.  
 
 
4.4  Results and Discussion 
4.4.1 CO2 gas measurements  
The CO2 gas measurement profiles are shown in Figure 4.2, containing oral, gastric and 
small intestinal divisions. Non-lactase and lactase simulations are presented in separate 
graphs. As previously mentioned, two different bacterial populations are used for 
representing digestion within different regions of the SI. The gas profiles are described 
as: Figure 4.2(a) non-bacterial or chemical only, Figure 4.2(b) 106 CFU bacterial 
population size, and Figure 4.2(c) 109 CFU bacterial population size. Figure 4.2(d) 
shows the dominant source of gas production (either chemical or bacterial) from the 
bacterial simulations, obtained via the subtraction of the bacterial CO2 profiles from the 
chemical only (non-bacterial) profile. 
 
4.4.1.1  CO2 in oral phase and gastric phase  
Little CO2 production is observed within the oral phase as a result of the short duration 
with CO2 measured within the gastric phase is < 1 ml of production. 
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4.4.1.2  CO2 in the SI phase 
From Figure 4.2(a-c), the highest production of CO2 for the SI phase occurs within the 
non-bacterial simulations. The NaHCO3 present within the injected SI fluid chemically 
react with HCl content of the gastric digesta to increase the pH from 3 (within the 
gastric phase) to near neutral. The chemical equation in which the NaHCO3 and HCl 
interact can be found from equation (1) (from section - 3.4.1 Gas production profiles)  
 
Another source of CO2 production is the interaction of NaHCO3 and the free fatty acids 
found within the SI digesta [20]. These free fatty acids are the products of lipid 
digestion. Triglycerides are denatured in the gastric phase and enzymatically cleaved 
throughout the SI phase, resulting in side chains that interact with the NaHCO3, 
producing CO2 as a by-product [20]. 
 
In non-bacterial case, after 4 hours, the measured CO2 from the gastric phase reached 
12.92 ml (non-lactase, p < 0.05) and 9.02 ml (lactase, p < 0.05) as can be seen in Figure 
4.2(a). An interesting observation is the reduction of CO2 production in the presence of 
the lactase enzyme. The addition of lactase in the chemical only simulation reduced CO2 
production by 30.2 %. This reduction may be due to the fact that the lactase protein 
molecule has many functional groups on its surface and as such operates as a weak 
buffer to neutralise the added NaHCO3, hence reducing the CO2 production [21]. 
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Figure 4.2 - CO2 gas profiles for (a) non-bacterial simulations; (b) 106 CFU bacterial simulations; (c) 109 CFU 
simulations, and; (d) dominant source (chemical or bacterial) of gas production (This graph is was obtained via 
subtraction of the bacterial production from the non-bacterial production).  The digestion phases within each 
simulation are represented by colours: white – oral phase, dark grey – gastric phase, and light grey – SI phase 
 
The CO2 production of the 10
6 CFU simulations shows an overall decrease in total CO2 
production in comparison to their associated non-bacterial case. Compared to the non-
lactase non-bacterial CO2 profiles, the decrease was 28.5%. This decline can be 
attributed to the presence of the bacteria. The bacteria produce enzymes and proteins, 
and contain embedded proteins in their lipid bilayer membranes, that are suggested to 
act as weak buffer [21]. This contributes to the neutralizing effects on the digesta and as 
a result, less net NaHCO3 is consumed, resulting in lower CO2 production, according to 
equation (1). It is important to consider that both Lactobacillus acidophilus NCFM and 
Bifidobacterium lactis Bi-07 are homo-fermentative bacterial and do not metabolically 
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contribute to CO2 production [22], producing more lactic acid instead. This can also 
contribute to the reduction of this gas. 
 
A larger and more noticeable reduction in CO2 production was observed with the lactase 
based 106 CFU simulations in comparison to non-lactase case. This reduction of CO2 
production was to almost a half (46.1%) of the non-bacterial non-lactase CO2 
simulations. With the addition of the lactase enzymes, there are more proteins present, 
increasing the buffering effects and hence further reducing CO2 production [21]. A 
relatively fast proliferation of bacteria, which will be shown later, may also contribute 
to the production of more lactic acid. 
 
In the non-lactase 109 CFU case, the decrease in the CO2 production is 19.0%, which is 
9.5% lower than the 106 CFU case. When lactase is present in the 109 CFU simulation, 
the drop in the overall CO2 production is similar for both 10
6 CFU (46.1%) and 109 
CFU (39.8%) bacterial concentrations.  
 
Figure 4.2(d) is extracted by subtracting the bacterial simulations from the non-bacterial 
simulations to provide a clearer depiction to ascertain the source of production 
(chemical or bacterial) in the CO2 profiles. In all cases, CO2 production is decreased in 
the intestinal phase when bacteria are present. The largest difference is seen when 
lactase is present and the bacterial concentration is 106 CFU. These observations are in 
good agreement with clinical observations in which the presence of lactase enzymes 
helps reduce cases of bloating [23, 24].  
 
The 106 CFU (non-lactase) and 109 CFU (non-lactase) plots as seen in Figure 4.2(d) 
(black and green traces, respectively) represent the impact of bacterial population 
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without the lactase enzyme. A relatively large difference can be observed between the 
pair themselves, with the 109 CFU simulation producing higher quantities of CO2. This 
can be ascribed to the increase in the bacteria population resulting in more bacterial 
produced CO2. This is a good example of digestion with lactase deficiency problems. 
The continued consumption of milk results in an increasing bacterial population within 
the gut [25, 26]. The bacteria themselves are able to produce enzymes to cleave the 
disaccharide and consume it [16]. The increase in bacterial population eventually 
reverses the CO2 reduction trend and inadvertently increases the amount of produced 
gas, based on Figure 4.2(d)’s 106 CFU (non-lactase) and 109 CFU (non-lactase) trends. 
This may result in symptoms such as bloating and flatulence which are key indicators of 
excessive gas production.  
 
The 106 CFU (lactase) and 109 CFU (lactase) pair within Figure 4.2(d) (red and blue 
traces, respectively) shows the impact of lactase on milk digestion in the presence of 
different bacterial population sizes. The difference between the 106 CFU (lactase) and 
109 CFU (lactase) pair themselves is small, suggesting that the impact of lactase vastly 
reduce CO2 production, even at even high bacterial populations. This is in agreement 
with the literature as many clinical trials, which use exogenous lactase as a form of 
primary treatment for lactase deficient patients, have shown significant drops in gas 
production via symptom severity surveys and indirect methods of measurement of 
breath CO2 [27-29]. 
 
4.4.1.3  H2 gas measurements 
Small amount of H2 is also produced during the in-vitro simulations. Both Lactobacillus 
and Bifidobacteria bacteria are known to be non-hydrogen producers [30] and 
consequently the H2 concentrations during the simulations are very small. Presence of 
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such a low concentration of H2 is not directly reported in any previous literature as the 
majority of past works on in-vitro fermentation, incorporating these bacteria, use 
systems that are either not equipped with very sensitive H2 measurement systems or not 
searching for trace amount of H2 [31, 32]. However, selected literature also refer to the 
existence of trace amounts of H2 as an end product [33]. Here, the significance of 
measurement of low concentrations of H2 is shown to be consistent with changes in CO2 
profiles.  
 
Similar to CO2 profiles in Figure 4.2, both non-lactase and lactase simulations are 
conducted for each case including: no added bacteria, 106 CFU and 109 CFU 
simulations, as presented in Figure 4.3(a-c), respectively. 
 
Figure 4.3(d) shows the dominant source (either chemical or bacterial) of H2 gas 
production. This determination is achieved by subtracting the bacterial H2 profiles from 
the non-bacterial H2 profiles. From the subtractions, positive results indicate H2 
production was primarily due to a small bacterial fermentation.  
 
4.4.1.4  H2 in oral phase and gastric phases 
The production of H2 gas within the oral phase is not quantified due to the short 
duration of the phase across all digestion experiments. Some quantities of H2 are 
measured within the gastric phase in all digestion simulations. At this point, all 
digestion simulations contain the same constituents, and as none of the chemicals used 
are known to generate H2 upon chemical reaction with the added HCl, it is more likely 
that the sensor response was due to low level crosstalk from the acidic vapours that 
produce H+. The thermal conductivity sensor used partially operates based on the 
breakdown of H2 on its catalytic surface. 
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4.4.1.5  H2 in the SI phase 
From Figure 4.3(b-c), trace quantities of H2 are observed with the 10
9 CFU simulations, 
producing the largest values of 229.2 L in simulations without lactase and 219.4 L  
(p = 0.52) with lactase. The statistical significance between the 109 CFU and the lactase 
109 CFU digestion simulations was much lower than the other H2 gas profiles as the 
sample size was n=3. However, the temporal H2 production information was able to 
demonstrate features which are discussed further on. This was followed by the lactase 
106 CFU simulations with 200.1 l (p < 0.05) and non-lactase, 167.3 l (p < 0.05) of H2 
production. The chemical only (or non-bacterial) simulations do not produce H2 
throughout the SI phase. From Figure 4.3(d), all the simulations were positive in value 
reflecting that all H2 productions within the SI phase are due to bacterial fermentation 
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Figure 4.3 - H2 gas profiles for (a) non-bacterial simulations; (b) 106 CFU bacterial simulations; (c) 109 CFU 
simulations, and; (d) Source (chemical or bacterial) of gas production (This graph is was obtained via subtraction of 
the bacterial production from the non-bacterial production). The digestion phases within the simulation are 
represented by colour: white – oral phase, dark grey – gastric phase, and light grey – SI phase 
 
In 106 CFU case, adding lactase seems to slightly increase the H2 production overall. In 
the presence of lactase enzymes, the lactose molecules within the digesta are 
glucosidically cleaved forming the monosaccharides glucose and galactose. Both 
monosaccharides are quickly metabolised by the bacteria. The absence of the lactase 
enzymes requires the bacteria itself to produce the necessary enzymes to break down the 
lactose before it can be metabolised. This increases presence of lactic acid as the 
substrate, and if the pathway exits, results in producing more H2.  
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The outcomes are consistent with the discussions obtained from exploring CO2 profiles. 
Despite knowing that the two strains used are mostly non-hydrogen producing bacteria, 
even trace measurements of H2 seem to be effective in in-vitro investigations.  
 
4.4.2 Continuous pH measurements 
The continuous pH measurements for all simulations are shown in Figure 4.4. After 
transition from the oral phase into the gastric phase, the SGF had initially lowered the 
pH of the digesta to between 5.6 and 5.8. This was noticed at the beginning of the 
gastric phase and an additional injection of 1.2 ml of 1 M HCl was immediately added 
to lower the gastric digesta to desired target pH of 3.0. The pH after this point was 
allowed the freely change within the current phase. The requirement for additional acid 
in the gastric phase is due to the milk containing a number of pH buffering components 
within milk itself including soluble phosphates, citrate, bicarbonate, casein and whey 
proteins [34]. Lucey et al. [35] have reported that in the pH range 6.7 to 4.0, whey 
proteins, colloidal calcium phosphates, and casein contributed approximately 47%, 21% 
and 32%, to the buffering effects in milk. No additional acid or base was used during 
the gastric or SI phases. 
 
The measured pH in the oral phase was 7.0 for all simulations with very little pH 
change within the short duration of the phase. The gastric phase also exhibited very 
little change.  
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Figure 4.4 – (a) pH profile of digestion simulation, and; (b) the % change in pH from t > 3 h. 
 
After introducing the SI fluids into the digestion simulator unit, the pH increased from 
the gastric phase of 3.0 to a target of ~7.0. The pH within the SI started to stabilise at 
t=3 h. After stabilising, the pH in the phase showed a steady decline, indicating the 
digesta was slowly acidifying. The slow acidification of the SI digesta is an expected 
result as free fatty acids increase in concentration as the lipase enzymes within the SI 
fluid continue to cleave the milk lipids present within the digesta [36]. In simulations 
containing bacteria, end metabolic products like lactic acid also contributed to the 
acidification in this phase. 
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To better compare the degree of acidification with respect to the various digestion 
simulations, a reference point is established at the pH stabilisation time estimated at t=3 
h. The percentage change of pH for each digestion simulations at time t is calculated by: 
 
% 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑝𝐻𝑡 = (
pHt−pHt=3
pHt=3
) ∙ 100%        (𝑓𝑜𝑟 𝑡 > 3)   (2) 
 
where pHt is the current pH value of the observed milk digestion simulation, and; pHt=3 
is the pH value at t=3 h of the same observed milk digestion simulation. The results of 
the pH percentage changes can be seen in Figure 4.4(b).   
 
Acidification of milk digestion simulations shows a trend towards two distinct groups, 
with lactase being the determining factor. For non-bacterial simulations, the lactase 
enzyme physisorbs NaHCO3 resulted in less net acid neutralisation. With bacteria 
present, the lactase also facilitated ready-to-metabolise monosaccharides increasing the 
quantity of end-metabolic products, which additionally lowered the pH within the 
digesta.   
 
4.4.3 Bacterial count comparisons 
From Table 4.4, the bacterial growth for the 106 and 109 CFU samples, for both non-
lactase and lactase milk digestion simulations. For the bacterial simulations inoculated 
with 106 CFU, the bacterial growth was 3.3  107 and 6.1  107 CFU for the non-lactase 
and lactase simulations, respectively. The impact of lactase within the 106 CFU 
simulation demonstrates a 1.9 times increase in bacterial population growth. The 
bacteria’s ability to process and consume nutrients is a limiting factor in the rate of 
bacterial proliferation [37, 38]. Complex nutrient structures require additional time and 
resources to break down into the mono- form for bacterial consumption. In the lactase 
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106 CFU simulation, promoted monosaccharides from glucosidically cleaved lactose are 
vastly easier to metabolise. With these reserves of monosaccharides in the digesta, the 
bacteria are able to significantly boost proliferation rates. The behaviour is reflected in 
the first 30 minutes after gastric-SI transition in the H2 profiles found in Figure 4.3(b). 
 
However, the simulations inoculated with 109 CFU, both non-lactase and lactase 
simulations show very similar bacterial growth. The slight difference may be due to the 
physisorption of lactase onto the surface of bacteria [21], as discussed in relation to CO2 
measurement.   
 
A general bacterial growth comparison can be made for all bacterial simulations by 
comparing the bacterial growth ratio: 
 
𝐵𝑎𝑐𝑡𝑒𝑟𝑖𝑎𝑙 𝑔𝑟𝑜𝑤𝑡ℎ 𝑟𝑎𝑡𝑖𝑜 =  
Bacterial growth (CFU)
Inoculum (CFU)
   (3) 
 
where ‘bacterial growth (CFU)’ refers to the bacterial growth values in, and ‘inoculum 
(CFU)’ refers to the inoculum bacterial count found in Table 4.4. Based on the 
calculated growth ratios, the most significant was the CFU 106 with lactase. This 
simulation shows the greatest reduction in CO2 and the largest decrease in the pH which 
indirectly suggests higher production of lactic acid which is in agreement with the rest 
of characterisation. 
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Table 4.4 - Bacterial growth from milk digestion simulations 
 Inoculum (CFU)* Bacterial growth (CFU)* 
Bacterial 
growth ratio 
106 CFU non-
lactase 
1.02  106 ± 8.16  104 3.26  107 ± 1.95  106 31.9 
106 CFU lactase 1.00  106 ± 5.01  104 6.08  107 ± 2.13  106 60.8 
109 CFU non-
lactase 
1.09  109 ± 6.07  107 4.45  1010 ± 7.38  109 
40.9 
109 CFU lactase 1.01  109 ± 9.49  107 3.71  1010 ± 9.28  109 36.7 
* error was calculated by mean ± std. dev 
 
4.4.4 Raman spectrum analysis 
Raman spectroscopy is used for analysing the outcomes of the simulations in the search 
for Raman peaks that are associated with the milk proteins (whey and casein), lipids 
(milk triglycerides, free fatty acids) and lactose. In order to compare and identify 
changes within the Raman spectra of the milk digesta, several baselines are obtained 
including milk substrate, spectra at the end of gastric phase and the digesta at the start of 
the SI phase (before simulations variants such as lactase and/or bacteria was added). 
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Figure 4.5 - Raman spectra for milk digestion simulations. Samples are analysed at different phases 
throughout the simulations 
 
Figure 4.5(a) shows the Raman spectra of milk used within the simulations which 
reflects a combination of known peaks relating to its constituents. Notable peaks that 
occur are: 360 cm-1 (lactose), 1552 cm-1 (milk triglycerides) and 2925 cm-1 
(whey/casein proteins) [39]. Figure 4.5(b, c) show the Raman spectra of the digesta at 
end of the gastric and start of the SI phases. Figure 4.5(d-g) are the spectra of the final 
digesta for the non-bacterial and 109 CFU bacterial milk digestion simulations. The 106 
CFU Raman spectra are not included as spectral changes and peak identifications are 
the same as the 109 CFU but smaller in magnitude. 
 
Figure 4.5(b) shows the spectra of the milk digesta at the end of the gastric phase. 
Comparing the milk reference to the gastric digesta spectra, we observe decreases in 
peak heights with respect to the whey/casein peak at 2925 cm-1. This is expected as 
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proteins denature and are enzymatically cleaved by pepsin within the gastric phase of 
digestion. The lactose peak is still present as they appear to not breakdown within the 
gastric phase. Figure 4.5(c) shows the spectra of the milk digesta after transitioning 
from the gastric to the SI phase. Further reductions in the whey/casein peak occur as 
well as reductions in the triglyceride peak take places due to presence of pancreatic 
enzymes. The spectra also show peak formations at 486 and 600 cm-1 which can be 
attributed to the increase in mono-glycerides and free fatty acids (FFAs). These peaks 
are reflected for all SI digesta spectra (Figure 4.5(d-g)) [40].  
 
In the lactase non-bacterial simulation, Figure 4.5(f), a large peak formation occurs at  
2883 cm-1, double the height of the non-lactase (non-bacterial) simulation shown in 
Figure 4.5(d). With the introduction of lactase, lactose molecules are glucosidically 
cleaved, resulting in glucose and galactose. Both monosaccharides have dominant 
Raman spectrum peaks at 2883 cm-1 [41, 42]. The doubling in height shown in Figure 
4.5(f) is a reflection of the fact that lactose hydrolysis results in two additional 
molecules with the same dominant Raman peak. Further still, evidence of the bacteria’s 
ability to monopolise on the freely available monosaccharides is seen in Figure 4.5(g), 
the lactase (109 CFU) spectrum, with the large reduction of 2883 cm-1 peak. 
 
4.4.5 NMR spectroscopy analysis  
The bacterial metabolites and short chain fatty acids (SCFAs) within the milk digesta 
after digestion simulations are quantified using NMR spectroscopy. In particular, the 
SCFA’s and amino acids are of interest as they can provide insight to the fermentation 
condition within the simulations. Quantitative estimates are measured with the aid of the 
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Human Metabolome Database [18]. To ensure a measure of consistency within the 
estimates, the NMR analysis is carried out in duplicate. 
 
Quantification of the simple amino acids and SCFA was completed on the milk digesta 
samples and can be seen in Table 4.5. No simple amino acids or SCFA is detected in the 
pure milk sample. Amino acids and SCFA are produced once milk undergoes in-vitro 
digestion (with and without the presence of bacteria).  
 
No particular change or trend is observed for citrate, phenylalanine and tryptophan. 
Propionate and formate are not detected in any of the digesta samples. Similarly, acetate 
could not be detected for non-bacterial case. However, acetate is present for all other 
cases but could not be quantified. Butyrate measurements are the highest for the non-
lactase non-bacterial case but are reduced in the bacterial digesta samples. It is possible 
that the presence of the bacteria reduced the rate in which milk lipids are reduced into 
the SCFA forms either by consumption via bacterial lipid metabolism or an inhibiting 
mechanism slowing lipase activity.  
 
Lactic acid, as expected, has the least increase for non-lactase 106 CFU sample in 
comparison to other simulations. This is expected as this simulation also resulted in the 
lowest change in pH within the SI phase and also the lowest H2 production of all 
bacterial simulations.  
 
Altogether, trends for butyrate and lactic acid confirm that the in-vitro simulation 
resulted in expected outcomes [43]. 
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Table 4.5 - NMR metabolite analysis of the simulated milk digesta 
 Concentration (µmol/l) 
Metabolites 
Identified 
Milk 
(ref) 
Milk 
(non-
bacterial 
– non-
lactase) 
106 CFU 
106 CFU 
lactase 
109 CFU 
109 CFU 
lactase 
Acetate 1ND ND b b b b 
Formate ND ND ND ND ND ND 
Lactic acid ND ND 
1870.5  
287.2a 
2191  
33.9 a 
2592.5  
183.1 a 
2174.5  
115.25 a 
Butyrate ND 
10567  
624.3 a 
7938  
619.4 a 
8016.5  
634.9 a 
8625.5  
301.9 a 
7810  
211.4 a 
Citrate ND 
2351  
271.4 
2854  
634.8 
3088  
330.9 
3056.5  
265.2 
2733  
224.2 
Lysine ND 
2133  
274.6 a 
3698  
793.4 a 
3930  
135.8 a 
4194  
540.2 a 
3691.5  
176.1 a 
Phenylalanine ND 
887    
46.7 a 
711.5  
21.9 a 
826  
15.6 a 
755.5  
47.4 a 
754  
77.78 a 
Propionate ND ND ND ND ND ND 
Tryptophan ND 
465   
128.5 a 
571.5  
118.1 a 
516  
43.8 a 
526.5  
46 a 
492.5  
50.2 a 
Tyramine ND 
863   
124.3 a 
978.5  
33.2 a 
1159  
19.9 a 
1185  
108.18 a 
1175.5  
48.8 a 
Values are presented as mean  std.  
1 ND means not detected 
a Concentration over-calculated due to peak overlap 
b Metabolite observed but concentration could not be determined 
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4.5  Further evaluation of the author’s in-vitro digestion 
simulator  
The H2 measurements taken during the milk digestion simulations were of a lower 
concentration compared to the model carbohydrate simulations in section - 3.4.1 Gas 
production profiles. Increasing the H2 sensor’s operating voltage had vast improvements 
in the stability and reliability of the measurements despite the reduced H2 sensitivity and 
increased non-target gas cross-talk [9]. Also, the increased gas quantities via increased 
food and simulated digestion fluid quantities had a positive effect on the sensor’s 
performance. Smaller error bars were observed within the milk digestion simulations 
compared to the model carbohydrate simulations in section - 3.4.1 Gas production 
profiles. Larger quantities of gas within the headspace intrinsically improves the signal-
to-noise ratio of the sensors, producing stable and repeatable measurements. 
 
The 2 hours extension of the SI phase duration was also successful as it provided 
enough time to demonstrate the bacteria’s effect on gas production profile and bio-
chemical and metabolomic impact on the small intestine digesta. The SI phase extension 
was highly successful for Raman analysis as it was able to identify key peaks relating to 
the milk constituents. Further still, it was able to clearly observe the milk food-matrix 
breakdown and bacterial consumption of the local carbohydrates (lactose, glucose, and 
galactose). However, the NMR analysis was only partially successful in that it could 
clearly identify the SCFA (and key amino acids) but struggled to quantify the levels 
within the simulated digesta samples. 
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4.6  Considerations regarding in-vitro simulations and future 
work 
While the current digestion simulation setup provides for real-time logging of gas 
production for analysis of gas biomarkers and pH data, the digestion protocol used in 
this work did not include some of the physio-digestive conditions that occurs to food 
while transiting between digestion phases.  The transitions between oral, gastric, and SI 
phases were instant due to the direct injection of the simulated digestive juices which is 
not representative of dynamic pH changes or timings involved that better simulate an in-
vivo digestion [44]. The potential to further expand on this in-vitro digestion setup is 
vast, including the capacity to connect programmable syringe pumps or automated 
injection systems to the Luer lock injection port. Such modifications to the protocol and 
system should be implemented in future simulators to provide a better representation of 
the gut.  
 
It is also important to consider the impact on gas production due to physio-digestive 
aspects of digestion such as effect of food particle size and impact of peristaltic forces 
(gastric and/or small intestine) throughout the digestive simulation process that should 
be further explored. 
 
Another limit to the work undertaken was the simplified bacterial model used. While 
the bacteria selected are the major groups found in the SI, greater diversity is required to 
draw more meaningful conclusions about the impact the microbiome has on digestion 
and gas production. 
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4.7  Conclusions 
This proof-of-concept study shows the usefulness of the developed upper gut simulator 
with the ability of continuous gas measurements. The viability of the system was 
demonstrated using milk digestion, with/without lactase and with/without the SBM. The 
outcomes of the gas sensing simulations were further explored using NMR and Raman 
spectroscopy.  For the CO2 profile, the largest concentration of gas was produced via 
chemical reactions when no lactase or bacteria were present. Simulations that contained 
lactase always resulted in a reduction of CO2. The lowest CO2 production was when 10
6 
CFU bacteria and lactase were both included. Such outcomes are in agreement with 
common observations in the consumption of milk in lactase deficient individuals, where 
milk digestion causes discomfort due to the excessive production of gas. In simulations 
that contained low concentrations of bacteria (106 CFU), lactase helped in effectively 
reducing CO2 gas production. All such observations are in agreement with clinical 
observations, showing the value of in-vitro simulators with incorporated gas sensors. In 
an additional observation, we saw that the measurement of trace H2 production in the 
simulations could also be correlated to the bacterial and lactase enzyme activities as no 
H2 was produced in the non-bacterial simulations.  
 
Overall, the proof-of-concept shows promise for our developed continuous gas 
monitoring platform that is able to provide insightful responses of gas biomarkers to 
identify fermentability and digestibility that can be extended to different types of foods. 
The results were reliable and repeatable. In the future, the system design can 
accommodate different in-vitro digestion schemes to target drug and pharmaceutical 
testing applications or assessing food nutrition in different diet regimes. 
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Chapter 5 - An in-vitro investigation of gas production 
between simple and complex bacterial models in the 
upper gut 
5.1  Introduction 
 
In chapter’s 2 and 3, the author’s novel upper gut in-vitro digestion simulator was 
outlined consisting of custom machined simulator equipment, gas sensors, and digestion 
protocol. The in-vitro digestion simulator was then evaluated using three model 
carbohydrates and comparing the outcomes with the current literature available on 
upper gut carbohydrate digestion. Through observations from these simulations several 
improvements were identified including changes to the H2 sensor configuration for 
better performance. 
 
In chapter 4, the in-vitro digestion simulator was evaluated as an exploration tool and 
diagnosis of gas production outcomes within the SI. The author’s in-vitro digestion 
simulator was evaluated the in-vitro digestive outcomes of a commonly consumed, 
well-studied food – cow’s milk. Observed gas production profiles, pH profiles, and 
other characterisations demonstrated digestive outcomes that align with current 
literature and clinical observations. Increased gas production trends emerged with 
simulations containing higher than normal bacterial content. Especially in simulations 
without lactase, such scenarios have been clinically observed to result in gut symptoms 
such as bloating and excessive flatus. 
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In this chapter, an investigation of the bacterial fermentation capacity is investigated 
with the introduction of a second bacteria model. The multi-strain bacteria model 
(MSM) used in the simulations represents the bacteria community typically found 
within lower gut, near the distal SI and cecum regions, typically where bacterial 
fermentation dominates the gas production process. Bacterial strains from MSM is not 
typically found in the upper SI tract of a healthy gut but is common in varieties of gut 
disorders such as small intestine bacterial overgrowth (SIBO)[1, 2]. SIBO is defined as 
a bacterial population in the proximal jejunum exceeding 106 organisms/mL [3, 4]. 
Typically, low populations of bacteria exist in the proximal jejunum (103 CFU/mL) with 
the majority of these being Gram-positive organisms [3]. Apart from the population 
sizes that inhabit the proximal jejunum, the type of microbial flora present also plays an 
important role as the communities of bacteria that become predominant transition to 
those found in the distal ileum [5, 6].  
 
Typically, SIBO is prevalent with other gut disorders which can presents additional 
gastrointestinal symptoms which can mislead diagnosis [6]. Further still, SIBO can 
negatively impact on the outcome of dietary interventions for managing gut disorders. 
Due to the difficulty of diagnosing SIBO, it is currently reported that the prevalence of 
SIBO in patients diagnosed with irritable bowel syndrome (IBS) was reported in the 
range of 4%-78% [7]. In patients that have Celiac disease, SIBO was found to coexist in 
50% of the cases resulting in gastrointestinal symptoms despite shifting to a gluten 
avoidance diet [8].  
 
The simulations utilise the three model carbohydrates used in chapter 3 in combination 
with the MSM and SBM to investigate the potential of using gas biomarkers to identify 
non-SI native flora and SIBO conditions. Each model carbohydrate is simulated in four 
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conditions: 106 CFU SBM, 109 CFU SBM, 106 MSM, and 109 MSM. The explanation 
of the four conditions are explained below. The use of gas production and rate of 
production profiles is to find key features and trends that can clearly identify each of 
these cases. 
 
In this in-vitro digestion investigation, the 106 CFU SBM is considered to be the 
scenario which represents the native SI flora at healthy bacterial populations. 
Conversely, the 109 CFU MSM represents the presence of SIBO within the SI. The 106 
CFU MSM represents the case where there are non-SI native bacteria present but at low 
population levels. Lastly, the 109 CFU SBM represents the presences of native-SI flora 
but at high population levels. 
 
Key results from the CO2 gas production and rate of production profiles reveal distinct 
features that vary with bacteria model and bacteria population size. The inulin CO2 
production features a ‘double peak’ within the rate of production profiles. The 
combination of high sample rate temporal gas production profiles and rate of production 
profiles greatly expands the potential ‘digestive information’ that can be obtained from 
the in-vitro digestion simulations.  
 
Within this work presented here, the aims were to investigate and compare the digestive 
outcomes of the two bacterial models representing the upper SI tract and the lower SI 
tract within the simulated SI phase of digestion. In particular, the observation and 
analysis of gas production profiles to potentially identify key features that may help in 
increasing our current understanding of how SIBO can present within the upper 
digestive tract.  
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It is important to address that the in-vitro digestion simulation protocol used in this 
work combine the duodenum, jejunum, and ileum together in a single digestive phase. 
Despite the definition of SIBO specifically describing the proximal jejunum, the work 
undertaken in this chapter looks at relative differences between digestive outcomes of 
the upper SI bacteria model and the lower SI bacteria model with the perspective of 
identifying key features and differences that can potentially, uniquely identify the nature 
of the bacterial communities under simulation. 
 
5.2  Materials and methodology 
The materials used in the in-vitro digestion simulation were of technical grade and 
purchased from Sigma Aldrich. The digestive enzymes used were Amylase (38000 
U/mg), pepsin (10000 U/mg), pancreatin (USP×1) which were purchased from Southern 
Biological (Australia). The carbohydrates used within the digestion simulations were 
glucose, fructose, and inulin. The glucose powder was purchased from Merck. The 
fructose and inulin powder were purchased from The Melbourne Food Depot 
(Australia). 
5.2.1 Bacteria models 
The SBM has been used in previous digestion simulations for gas production 
investigations in which the bacterial model strains and bacterial population size chosen 
is covered in section - 2.9.3.1 Use of bacteria in the SI phase. As discussed in the 
aforementioned section, the low bacteria SBM (or 106 CFU SBM) was used as a 
‘healthy gut’ reference.   
The MSM used in this work contains 15 strains and was chosen based on the strains 
commonly found within the distal SI where bacteria fermentation is dominant [9, 10]. 
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The inoculum was sourced from a commercial probiotic product (Life space’s Broad 
Spectrum Probiotic, Life space). 
 
5.2.2 In-vitro simulation 
The assessment of fermentation capacity of the upper gut utilised the model 
carbohydrates glucose, fructose, and inulin as food stimuli and was primarily 
investigating the real-time CO2, H2, and pH profiles. The ‘rate of gas production’ 
profiles are also introduced in this work as another perspective to identify key trends 
and features occurring within the digestion simulations. In particular, to identify periods 
within the simulation where chemical digesta equilibrium has occurred within the 
digestion simulation but bacterial fermentation is still occurring. Other characterisations 
were conducted to help evaluated the overall digestive outcomes including bacteria 
counts and gas chromatography analysis of short chain fatty acid (SCFA).  
 
The investigation looked at the digestive outcomes for glucose, fructose, and inulin with 
the central focus around the two bacteria models (SBM and MSM) at low bacterial 
populations (106 CFU) and high bacteria populations (109 CFU). Each simulation was 
repeated in triplicate (n=3). The preparation of SBM bacteria inoculum, equipment 
setup, and pressure testing were completed as per the section - 2.9 Simulation protocol. 
The MSM bacteria inoculum preparation and usage is discussed in section - 5.2.3 Use 
of bacteria in the SI phase. 
5.2.2.1  Oral phase 
SSF was prepared using the modified method outlined in section – 4.2 In-vitro digestion 
simulation improvements (Table 4.1). Model carbohydrate under simulation was mixed 
with water at a ratio of 1:1 (W(g): V(mL)). A 15 mL aliquot of the mixture was placed 
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in the digestion simulator to brought up to temperature. The digestion simulation starts 
with the injection of 15 mL of SSF into the reactor, which was incubated at 37 °C for 
5 min agitated at 0.5 rpm. 
5.2.2.2  Gastric phase 
SGF used in the gastric phase was also prepared via the modified method in section – 
4.2 In-vitro digestion simulation improvements (Table 4.2). After the oral phase was 
complete, 30 mL of SGF was added to the vessel and incubated for 2 h. The target pH 
of the gastric phase was 3.0 and where required, 1 M HCl was added to lower the pH.  
5.2.2.3  SI phase 
SIF was also prepared using the modified method outlined in section – 4.2 In-vitro 
digestion simulation improvements (Table 4.3). After completion of the gastric phase, 
60 mL of SIF was injected into the digestion simulation giving a total volume of 120 
mL. If pH adjustments were required, the addition of 1 M NaOH or 1 M HCl was 
added. The SI simulation was incubated at 37 °C for a final 4 h.  
5.2.3 Use of bacteria in the SI phase 
For digestion simulations that were investigating the impact of bacteria, the incubated 
inoculum was added to the reactor after SI phase transition and after the SIF was added. 
 
The preparation of the MSM inoculum was done via emptying a whole probiotic 
capsule into 50 mL of cold (4 oC) DI water. The inoculum was prepared on the day and 
stored at 4 oC until required. To compensate for bacterial lag phase, the MSM inoculum 
was incubated (37 oC) for 2 h prior to the SI phase.  
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5.2.4 Bacterial growth assay 
Dilutions of the end SI digesta were plated using MRS agar (110660, Merck Millipore) 
via the pour plate method. Each plate was incubated for 48 h at 37 °C in anaerobic 
conditions (N2) and completed in triplicate with colonies counted by hand. 
 
5.2.5 Gas chromatograph (GC) analysis of SCFA 
The concentrations of SCFA from the end SI digester samples were analysed by a 
Bruker Varian 450-GC with a CP 8410 sampler equipped with a flame ionization 
detector and a 30 mm  0.25 mm ZB-FFAP fused-silica capillary column. Digester 
samples were filtering through a 0.22 µm membrane injection filter. An aliquot of 998 
µL quantity was then extracted and 2 µL of ethanol (internal standard) was added. The 
solution was thoroughly mixed using a vortex sonicator. All samples were prepared and 
analysed in triplicate. The main analytes of the GC analysis were acetate, propionate 
and butyrate as they are key primary by-products bacterial fermentation. SCFA profiles 
are known to change their ratios between the analytes with respect to food-types, 
bacteria strains, and environmental stressors [11, 12]. 
 
5.2.6 Data processing and statistical analysis 
Analysis of the gas production and rate of production were completed according to [13] 
with minor modification. To avoid over-filtering distortions from the method used in 
[13], the raw rate of production data (obtained via gas production profile derivation) 
was first separated into their digestive phases (i.e. the oral, gastric, and SI phases). Each 
phase was then processed with the ‘percentile filter’ [14]. The filter parameters were: 
Window size - 256 points, percentile threshold - 50%, and; Boundary condition was set 
to ‘None’. The individualised sections were then filtered using Matlab 2016B as per 
[13] and recombined.  
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5.3  Results 
The digestion simulation was conducted for three carbohydrates assessing their gas 
production and pH profiles for two bacteria models. CO2, H2 and pH were continuously 
measured during these periods. The bacteria growth assay and SCFA analysis were 
observed at the end of the SI phase for all digestion simulations. Despite the key interest 
within the SI phase where the bacteria models are active, the oral and gastric phases 
were conducted to ensure that any accumulated effects occurring are included in the SI 
digestion phase. 
 
 
5.3.1 CO2 gas production profiles 
CO2 production occurs from both chemical reactions and specific fermentation by-
products from bacteria strains, typically not found or in very low populations within the 
SI tract. The use of CO2 as a biomarker can help provide information about the way the 
bacteria in the SBM and MSM are interacting with the model carbohydrates under 
digestion simulations providing. Specific temporal features and patterns can be 
observed within the SI phase relating to bacterial models and size of population. Due to 
the small magnitude of production within the SI phase, a zoomed in figure was created 
to better observe the unique features. The CO2 gas production and the calculated rates of 
production from the simulation are displayed in Figure 5.1, with the zoomed in version 
of the SI phase displayed in Figure 5.2. A table summarising the end-phase CO2 
production quantities can be seen in Table 5.1. 
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Figure 5.1 - CO2 gas production profiles (left side) and CO2 rate of production (right side). The simulations were done 
for (a) glucose, (b) fructose, (c) inulin. Colours of the graph represent different digestive phases – White – oral phase, 
light grey – gastric phase, and; dark grey is the SI phase. 
5.3.1.1  CO2 gas production and rates of production in the oral phase 
Very little CO2 gas production was observed within the oral phase as the production 
was on the lower limits of the sensor’s range. As such, there is little rate of production 
information that can be obtained within this phase. Very little interaction between the 
model carbohydrates and the SSF was expected as the model carbohydrates are in their 
mono-form (glucose, fructose) or are not enzymatically cleavable by the local enzyme 
amylase. 
 
5.3.1.2  CO2 production and rates of production in the gastric phase 
Within the gastric phase of the simulations, the carbohydrate that produced the greatest 
CO2 production was the fructose (Figure 5.1b). Inulin showed the lowest production of 
CO2 (Figure 5.1c) within this phase as this was ascribed to the buffering influence of the 
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inulin substrate which slowly hydrolyses within the acidic digesta and reduces the 
protonic effect (section - 4.4.2 Continuous pH measurements).  
 
The rates of production for the oral-gastric phase transition and the settling time for the 
rates of production (when the rates of production reach zero) within the gastric phase 
largely vary within each carbohydrate simulation set. It can be assumed that the rate of 
oral digesta mixing with the introduced SGF was different per simulation resulting in 
the large variances. 
 
Table 5.1 – Average end-phase CO2 gas production for the oral, gastric, and SI  
Model 
carbohydrate 
Average 
Oral end-
phase CO2 
production 
(mL) 
Average Gastric end-
phase CO2 
production (mL) 
Average 
SI end-
phase 
CO2 
productio
n (mL) 
Average SI 
Percentage 
increase 
from 106 
CFU SBM 
Inulin MSM 
(109 CFU) 
- a 2.12 
2.07 ± 
0.13 
5.14 mL  
74.82% 
Inulin MSM 
(106 CFU) 
- a 1.94 3.30 mL  
12.24% 
Inulin SBM 
(109 CFU) 
- a 1.97 2.97 mL  
1.02% 
Inulin SBM 
(106 CFU) 
- a 2.20 2.94 mL  
N/A 
Glucose MSM 
(109 CFU) 
- a 3.49 
3.15 ± 
0.135 
2.89 mL  
186.13% 
Glucose MSM 
(106 CFU) 
- a 3.65 1.67 mL  
65.34% 
Glucose SBM 
(109 CFU) 
- a 3.51 1.66 mL  
64.35% 
Glucose - a 3.38 1.01 mL  N/A 
Fructose MSM 
(109 CFU) 
- a 4.04 
4.01 ± 
0.035 
2.19 mL  
247.61% 
Fructose MSM 
(106 CFU) 
- a 3.96 1.05 mL  
66.66% 
Fructose SBM 
(109 CFU) 
- a 3.98 0.87 mL  
38.09% 
Fructose SBM 
(106 CFU 
- a 3.97 0.63 mL  
N/A 
-a – CO2 measurements were below noise floor 
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5.3.1.3  CO2 production in the small intestine phase 
When transitioning to the SI phase of the digestion simulation, SIF is first added to the 
digestion simulator to neutralise the acidity of the gastric digesta and then the 
appropriate bacteria model and inoculum quantity was added immediately. As such, the 
resultant CO2 production from the small intestine phase can be seen in Figure 5.2(a-c, 
left). The CO2 rates of production for all three model carbohydrates can also been 
observed in Figure 5.2(a-c, right).  
 
 
Figure 5.2 - The SI phase of the model carbohydrate under digestion simulations. 
 
5.3.1.4  SI phase CO2 production – Inulin  
The largest quantities of CO2 gas production within the SI phase was from inulin 
ranging from 2.94 mL – 5.14 mL. This was followed by glucose and fructose with 
specific gas production quantities listed in Table 5.1.  Inulin is a highly fermentable 
substrate [15] with both SBM and MSM simulations producing the highest CO2 
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quantities out of the three model carbohydrates. Specifically, the bacteria within the 
MSM produce CO2 as a by-product of carbohydrate metabolism and naturally would 
produce higher quantities than that of the SBM simulations.  
 
Comparing CO2 production outcomes from Table 5.1, inulin produced a 1.01% CO2 
increase as the SBM bacteria population increase from low to high bacteria population. 
As no CO2 is produced from fermentation by the SBM. When changing to the MSM, 
the low bacteria simulation for inulin produced a large increase of 12.24% (with respect 
to the SBM 106 CFU simulation) in CO2 production. The MSM activity can further be 
observed in the inulin CO2 rate of production profile in Figure 5.2c (right) with a unique 
‘double peak’ feature at time t=2.9h. The first of the double peak feature coincides with 
the gastric-SI phase transition, implying that this CO2 rate of production peak is 
primarily driven by the acid neutralisation reaction (equation 1). As the NaHCO3 and 
HCl components within the digesta start to diminish, the CO2 production from bacterial 
fermentation begins to dominate, which drives the second rate of production peak. This 
double peak feature is observed for the inulin 106 MSM simulation but has a smaller 
second peak. This is likely due to the smaller bacterial population used for that 
simulation. This result reflects a level of selectivity with respect to the bacteria models 
under test.  
 
Current ex-vivo SIBO diagnosis methods that utilises H2 and radio-labelled CO2 breath 
testing make use of non-absorbable, highly fermentable substrates but have practical 
issues associated with the methodology [16, 17]. Specifically, quantities of non-
fermented carbohydrates within the SI that are not fermented transitions into the large 
intestine where the enormous bacteria population (1011 – 1012 CFU/mL [18]) rapidly 
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ferment the remaining carbohydrates, resulting it excessive gas production. This 
additional gas production is also measured making it difficult to decipher how much 
was produced in the small intestine phase. The excessive gas production within the 
large intestine is known to heavily affect the outcome of breath H2 and CO2 resulting in 
skewed results. 
 
However, the digestion simulations conducted here provide a perspective that observes 
CO2 production from within the SI. As such, the inulin digestion simulations conducted 
here reflect produce gas profiles that are distinctly different between the SBM and 
MSM via the CO2 production profile. As such, an in-vivo perspective from within the SI 
could potentially provide a gas production profile that could reflect the ‘double peak’ 
rate of production feature. 
 
5.3.1.5  SI phase CO2 production - Glucose  
The glucose produced a modest quantity of CO2 with end-phase productions ranging 
from 1.01 mL – 2.89 mL, which can be seen in Table 5.1. Both SBM and MSM 
simulations show an initial production of CO2 immediately after the gastric-SI phase 
transition which is attributed to the acid neutralisation reactions between the acidic 
gastric digesta and bicarbonate ions within the SIF (see equation 1).   
 
Comparing the low and high bacterial population SBM digestion simulations, the 109 
CFU simulation vastly increased the CO2 end-phase measured in the headspace by 
39.15%. Since SBM bacteria do not metabolically produce CO2, it is probable that 
increased population must have promoted dissolved CO2 within the digesta into the 
headspace. The low bacteria MSM digestion simulation also has a CO2 production 
increase of similar magnitude with 65.34%. It can be observed from Figure 5.2a, the 
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chemically driven CO2 production after the gastric-SI phase transition was initially 
lower than the 109 CFU SBM simulation. At time t= 3.25 h, the bacteria in the MSM 
began to dominate CO2 production within the simulation, increasing the CO2 rate of 
production resulting in a similar end-phase CO2 production as the 10
9 CFU SBM. The 
high bacteria MSM simulation also follows this trend but the CO2 production due to 
bacterial fermentation begins at an earlier time t=2.8 h. The rate of CO2 production is 
significantly higher in magnitude which can be seen in glucose rate of production 
profiles in Figure 5.2a. 
 
Despite glucose being a mono-form carbohydrate, the CO2 gas production profiles 
demonstrate unique trends that can clearly differentiate between SBM and MSM. When 
observing the 109 CFU MSM simulations compared to the inulin simulation 
counterpart, the glucose rate of production is much slower with peak bacterial 
fermentation rate of production reaching 0.675 mL/h after a period of 4 h within the SI. 
Against the inulin 109 CFU MSM simulation, the peak bacterial fermentation 
production rate reached 2.44 mL/h after 1.44 h into the SI phase.  
 
Although another unique CO2 production profile, the in-vitro digestion simulator does 
not simulate the rapid absorption that glucose naturally undergoes within the SI. 
Typically, glucose is a preferred substrate for the diagnosis of SIBO as the glucose that 
is not fermented by the bacteria within the SI is rapidly absorbed via the active transport 
mechanisms along the SI lumen [19]. Unlike the non-absorbable carbohydrates 
simulated, the mono-form carbohydrates (including glucose and fructose) will not be 
accurately represented due to the limitations of the in-vitro digestion simulator not 
being able to simulate active transport bio-mechanisms found in the SI lumen. 
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However, in extreme cases of SIBO where glucose absorption is minimal, validity of 
this mono-compartment simulator increases, potentially resulting in the slow-moving 
trends observed in Figure 5.2a (right). 
 
5.3.1.6  SI phase CO2 production – fructose 
Lastly, the CO2 production within the fructose simulations was slightly lower than the 
glucose simulations. The CO2 production for the fructose simulations ranged from 0.63 
mL – 2.19 mL (Table 5.1). Again, both SBM and MSM simulations show an initial 
production of CO2 immediately after the gastric-SI phase transition due to the gastric 
digesta and SIF contents mixing. However, the fructose CO2 production profiles 
maintain similar patterns but scale with the bacterial model and bacterial population 
size. This would suggest that the bacteria used within both models can rapidly 
metabolise the fructose, with it occurring at the same time period as the acid 
neutralisation reactions immediately after the gastric-SI phase transition.  
 
The peak rate of production (Figure 5.2b, right) magnitudes best represent the four 
different parametric simulations within the fructose carbohydrate investigation. The 
rates of production profiles for the fructose MSM simulations more visually manifest 
their syringe injection artefact with the large, sharp rates of production spike which is 
followed by a ‘shoulder’ formation. These artefacts were successfully filtered with the 
SBM simulations but was avoided in the MSM filtering due to profile over-filtering 
distortions. As such, these artefacts were left within the dataset. The fructose MSM 
rates of production was separately modelled and inserted into the figure representing the 
actual peak rates of production (which can be seen on the dotted red and dotted blue 
traces on Figure 5.2b, right).  
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When comparing low and high bacteria SBM production profiles, the was a large end-
phase CO2 production increase of 38.09%. Like the glucose low/high SBM profiles, the 
increase in bacterial population contributed to the promotion of dissolved CO2 into the 
reactor’s headspace. This is a positive result as it provides a large and well-defined 
increase identifying a change in population size. However, when comparing the low 
bacteria SBM simulation with the low bacteria MSM simulation, a massive increase of 
66.66% CO2 was observed. This increase was 1.75 times larger than then high SBM 
simulations and ~5.4 times larger than that of the inulin 106 CFU SBM – 106 CFU 
MSM CO2 comparison.  
 
With well-defined gas production and rate of production results, the fructose 
simulations have the same in-vitro simulation limitations as glucose. In-vivo absorption 
of these mono-form carbohydrates occur across the SI lumen reducing the potential net 
carbohydrates for SI bacteria fermentation. Despite the in-vitro simulation’s limitations, 
the fructose simulations demonstrate a vastly faster CO2 response that occurs 
immediately after the gastric-SI phase transition. Such a rapid gas production response 
is highly desirable in-vivo as prolonged gas production responses are susceptible to 
alterations via other in-vivo mechanisms (e.g. SI peristalsis). 
 
5.3.2 H2 gas production profiles 
H2 production is another regularly used gas biomarker for the clinical assessment of 
SIBO. Bacteria are generally the largest source of H2 production within the gut, 
especially from carbohydrate metabolisation [20]. H2 production and rate of production 
profiles can provide a unique perspective on identifying key features and trends between 
SBM and MSM behaviours. 
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Similar to the CO2 results section, the H2 gas production and the calculated rates of 
production from the simulations are displayed in Figure 5.3. To better observe key 
features and patterns within the SI phase, a zoomed-in figure of the H2 profile SI phase 
is displayed in Figure 5.4. A table summarising the end-phase H2 production quantities 
can be seen in Table 5.2.  
 
 
 
Figure 5.3 - H2 gas production profiles (left side) and H2 rate of production (right side). Again, the digestion 
simulations were completed for the carbohydrates (a) glucose, (b) fructose, (c) inulin. Colours of the graph represent 
different digestive phases – White – oral phase, light grey – gastric phase, and; dark grey is the SI phase. 
 
5.3.2.1  H2 production in the oral phase 
Close to no H2 gas production was observed within the oral phase. Due to the threshold 
of sensing for H2 being 0.02 mL, H2 rates of production within the oral phase were not 
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considered. Rates of production profile as that were calculated from H2 production data 
below 0.02 mL threshold shown but not considered. 
 
5.3.2.2  H2 production in the gastric phase 
With the introduction of the SGF, the H2 sensor begins to reliably read quantities of H2 
present within the reactor. The H2 produced within the gastric phase for all carbohydrate 
simulations can be seen in Figure 5.3(a-c, left). Similarly, the H2 gastric rates of 
production can be observed in Figure 5.3(a-c, right). 
 
As the gastric phase only contains the simulated digesta fluids (SSF and SGF) and the 
model carbohydrate under simulation, the gas production within this phase reaches 
steady state within the designated 2 h period. The end-phase production values for the 
gastric phase can be observed in Table 5.2. There are minor differences between the 
simulations’ H2 production within the gastric phase due to the impact of the model 
carbohydrates under digestion simulation. The differences themselves fall within the 
statistical error bars (Figure 5.3) and are not considered significant. 
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Table 5.2 - Average end-phase H2 production across the oral, gastric, and SI phases 
Model 
carbohydrate 
Average Oral 
end-phase H2 
production 
(µL) 
Average Gastric 
end-phase H2 
production (µL) 
Average SI 
end-phase H2 
production 
(µL) 
Average SI 
percentage 
increase from 
106 CFU SBM 
Inulin MSM 
(109 CFU) 
- b 91 
89.5 ± 
1.5 
114 
714.28% 
Inulin MSM 
(106 CFU) 
- b 90 45 
221.42% 
Inulin SBM 
(109 CFU) 
- b 89 78 
457.14% 
Inulin SBM 
(106 CFU) 
- b 88 14 
N/A 
Glucose MSM 
(109 CFU) 
- b 78 
75 ± 3 
77 
413.33% 
Glucose MSM 
(106 CFU) 
- b 75 29 
93.33% 
Glucose SBM 
(109 CFU) 
- b 77 30 
100.00% 
Glucose - b 72 15 N/A 
Fructose MSM 
(109 CFU) 
- b 115 
112.5 ± 
2.5 
38 
442.85% 
Fructose MSM 
(106 CFU) 
- b 110 29 
314.28% 
Fructose SBM 
(109 CFU) 
- b 113 24 
242.85% 
Fructose SBM 
(106 CFU 
- b 112 7 
N/A 
-b – H2 measurements were below noise floor 
  
5.3.2.3  H2 production in the small intestine phase 
After the gastric phase, SIF is added into the reactor to initiate the SI phase of digestion 
simulation. The addition of the bacterial inoculum was injected directly after the SIF to 
ensure the pH conditions in the reactor were conducive for the bacteria’s survival. The 
H2 SI phase of the digestion simulations can be seen in Figure 5.4. 
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Figure 5.4 - H2 gas profiles and rate of production profiles - the SI phase 
 
5.3.2.4  Inulin H2 production in the SI phase  
Unlike the CO2 production, both SBM and MSM only produce H2 from bacterial 
metabolism of carbohydrates. As such, the analysis of H2 production can provide useful 
trends/features via the production magnitude or rates of production. One such feature 
that was observed is the inulin H2 production with noticeable delays observed in Figure 
5.4c (right).  
 
Such delays in H2 production are a result of the bacteria’s rate of carbohydrate 
metabolism (which result in H2 as a by-product) reaching a point where the H2 sensor 
(TCD calorimetric sensor) can reliably register a response. As such, the delays observed 
in the inulin rate of production was noticeable for the SBM simulations with the longest 
delay (0.5 h) corresponding to the low bacteria population. This delay shortens to 0.18 h 
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with the high bacteria SBM simulation. Comparatively, the low and high MSM 
simulations show H2 production very quickly after gastric-SI phase transition. The H2 
production delays found within the rate of production profiles is an inulin specific 
feature which occur up to 0.5 h after the gastric-SI phase transition.  
 
Another limitation observed with the in-vitro digestion system is the specificity of the 
simulation. From an in-vivo perspective, the bacterial communities that occur can 
rapidly change in size and composition based on the most recent meal consumed [21]. 
Also, the ‘healthy’ bacterial communities found within the SI of individuals vastly 
varies between age, ethnicity, gender, and life style [22]. Despite these limitations, the 
in-vitro digestion simulation shows that complex, non-absorbable carbohydrates results 
in a delayed production of H2. Similar to SIBO assessment via breath hydrogen 
measurements reaching above a suggested threshold, which, at the time this thesis was 
written, is currently observed at >20 ppm above baseline [23, 24]. The possibility of 
observing a ‘delay’ threshold could be another potential viewpoint for the diagnosis and 
assessment of SIBO.  
 
 
5.3.2.5  Glucose H2 production in the SI phase  
 
Glucose H2 production within the SI phase was overall small in quantity with a ranged 
15 µL – 77 µL (Table 5.2). There were some noticeable trends towards the end of the SI 
phase with the low SBM and the high MSM simulations beginning to increase H2 
production. Despite these isolated trends, all simulations within the glucose 
carbohydrate simulations produced H2 immediately after the gastric-SI phase transition.  
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When comparing low and high SBM H2 end-phase productions, the H2 production 
doubles (100%) in quantity. When observing the H2 production increases for the low 
bacteria MSM, the gain is similar in magnitude with an increase of 93.33% (with 
respect to the low SBM simulation). From an in-vivo perspective, similar end-phase H2 
production increases between high SBM and low MSM simulations can make it 
difficult in assessing changes from SBM to MSM within the SI. 
 
5.3.2.6  Fructose H2 production in the SI phase  
For the fructose simulations, H2 production was the lowest out of the three model 
carbohydrates with a very small range of 7 µL – 38 µL. H2 production within the 
fructose simulations also occur immediately after the gastric-SI transition. From the H2 
rate of production profiles (Figure 5.4b, right), H2 production occurs in a relatively short 
period with rate of production profiles reaching zero within 1.5 h after phase transition. 
 
End-phase H2 increases for fructose shows a large increase of 242.85% (17 µL increase) 
when comparing low and high bacteria SBM simulations (Table 5.2). However, the 
difference between subsequent simulation (low MSM and high MSM) only ~5 µL 
increases. With the very small quantities of end-phase H2 produced within the fructose 
simulations, the use of H2 as a biomarker for observing changes in SI bacterial models 
would be challenging. 
 
5.3.3 pH profiles  
The pH profiles were monitored to ensure that the digestion simulations were operating 
within the digestion protocol parameters. Trends in the pH profiles can also provide 
insight into the chemical and bacterial changes that occur during simulation that may 
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result in gas production. The real-time pH profiles recorded at a rate of one sample per 
second for the carbohydrate digestion simulations are presented in Figure 5.5. The 
figure shows the overall pH profiles throughout the simulation duration, pH trends 
within the gastric phase, and; the normalised pH profiles within the SI phase (%pH). 
The point of normalisation for the SI pH profiles was visually observed to be the point 
where the pH profiles stabilise and is indicated with a white arrow at t = 3.8 h.  
 
Figure 5.5 - Carbohydrate digestion simulation pH profiles. (a) pH profiles for carbohydrate simulations across the 
oral (white), gastric (light-grey), and small intestine (dark-grey) phases; (b) Carbohydrate simulations within the 
gastric phase; (c) %pH change within the small intestine phase. 
 
The starting pH targets throughout the digestion simulation were 7.0 within the oral 
phase, 3.0 for the gastric phase, and 7.0 for the small intestinal phase. To observe any 
pH variation due to the influence of the food stimulus, a range of ±10% (of the target 
pH) was allowed before pH adjustment was made at the commencement of each phase 
if needed.  
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From Figure 5.5b, the gastric inulin pH levels were higher than the glucose and fructose 
simulations. This was expected as, according to Nilsson et al. [25], small quantities of 
inulin hydrolysis naturally occurs within the acidic environment. This results in a slight 
increase to the gastric digesta pH. Inulin’s effect on gastric pH has also been observed 
in other in-vitro digestion simulations [26].  
 
To better observe the pH effects that the SBM and MSM have on the small intestine, the 
pH percentage change (%pH change) (Figure 5.5c) was calculated based on equation 2 
(section - 4.4.2 Continuous pH measurements). The pH profiles were normalised at t = 
3.8 h (indicated by the arrow).  
 
After the normalisation, two main patterns emerged showing that low bacteria 
population simulations display positive pH increasing trends throughout the SI phase. 
Conversely, high bacteria population simulations demonstrated decreasing pH trends. 
The primary cause of this trend is the combination of the alkalising effects of the bile 
(found in the SIF) and acidic by-productions produced by bacterial fermentation (e.g. 
lactic acid and short chain fatty acids). In digestion simulations that contain initial 
bacteria concentrations of 109 CFU, the metabolic by-product production was large 
enough to overcome the alkalising effects of the bile, resulting in the negative %pH 
trend. In simulations where 106 CFU bacteria was used, the pH effects of the bile were 
slightly greater, an increasing and positive %pH change profile was observed.  
 
5.3.4 Bacteria growth assay 
To better understand the bacterial survival rates and to observe the bacteria’s preferred 
growth substrate, bacteria growth assays were conducted to see which model 
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carbohydrate best promoted the SBM and MSM. The bacteria used within the 
carbohydrate digestion simulations were inoculated at the start of the SI phase after the 
SIF had been added.  
 
The total population growth was measured after the SI phase with samples of the 
digesta immediately used to culture the MRS agar plates. The bacterial growths for the 
106 CFU (SBM and MSM) simulations and 109 CFU (SBM and MSM) simulations can 
be seen in Figure 5.6(a, b) respectively. To better observe and compare the growths of 
each of the digestion simulations, the growth ratio [27] was calculated and shown in 
Figure 5.6c.  
 
Figure 5.6 - Carbohydrate digestion simulation bacterial counts and growth ratios – (a) bacteria count for the 106 CFU 
SBM and MSM simulations; (b) bacteria count for the 109 CFU SBM and MSM simulations; (c) bacterial growth 
ratio 
 
Both 106 CFU and 109 CFU digestion simulations that used the SBM grew by a factor 
of 10-12 times from its inoculation. The model carbohydrate with the highest growth 
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factor for the SBM simulations was inulin. In contrast, the 106 CFU MSM specifically 
grew slightly better with a growth factor of 12 – 14 times, with highest growth 
occurring within the glucose simulation. The 109 CFU MSM growths were significantly 
larger with factors that were 19 – 22 times its inoculation population size with glucose 
carbohydrate performing the best.  
 
Despite fructose also being a mono-form carbohydrate, it had the lowest growth for 
both SBM and MSM. This would suggest that the bacteria in both models struggled to 
metabolise the fructose. With little H2 production observed from the fructose 
simulations (7 µL – 38 µL), this also would suggest that the bacteria in both models 
struggled to metabolise the fructose content.  
 
5.3.5 Gas chromatography and short chain fatty acid analysis  
The SCFA analysis was carried out on the small intestine digesta after the completion of 
each simulation (Figure 5.7). For carbohydrate-based simulations, SCFA compounds 
are unique by-products that are solely produced through bacterial fermentation. SCFA 
profiles provides a perspective on how metabolically active the bacteria models are 
during the simulations. 
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Figure 5.7 - SCFA analysis of SI digesta - quantities of acetic acid, propanoic acid, and butyric acid produced within 
the (a) glucose simulations, (b) fructose simulations, and; (c) the inulin digestion simulations. 
 
The SCFA profiles in Figure 5.7 follow two major trends, which are primarily based on 
the model carbohydrate chain-length. SCFA profiles for glucose and fructose generally 
demonstrated a large acetic acid production followed by butyric acid then propanoic 
acid. Inulin SCFA profiles demonstrated the opposite trend with large butyric acid 
quantities, then followed by propanoic acid and lastly, acetic acid. However, a change in 
mono-form carbohydrate SCFA profile pattern emerges with the 109 CFU MSM 
profiles as the second highest SCFA changes from butyric acid to propanoic acid. 
 
The substantial increase in SCFA present within the SI is a clear indicator that high 
concentrations of non-native bacteria are present. In the case of glucose and fructose 
simulations, a greater than two times the quantity of acetic acid was observed when 
comparing low bacteria SBM and high bacteria MSM. SCFAs would be another ideal 
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biomarker for the assessment of non-native SI flora and SIBO as SCFA are a primary 
metabolic by-product of carbohydrate metabolism.  
 
5.4  Conclusion 
This work presented in this chapter demonstrates the author’s novel real-time upper gut 
in-vitro digestion system as a potential tool for the investigation of gas production and 
rates of production profiles as a means to assess non-native SI flora and SIBO scenarios. 
Three model carbohydrates were simulated within the author’s in-vitro digestion 
simulator with specific emphasis on the bacteria models and bacteria populations sizes 
introduced into the SI phase of the simulation.  
 
CO2 production and rate of production profiles showed many promising features that 
allowed the identification of both SBM and MSM, but also low and high bacterial 
populations. In particular, the inulin CO2 rate of production profiles demonstrated a 
‘double peak’ feature that only appears in non-native SI flora (MSM) simulations. The 
magnitude of the feature’s second peak is directly related to the bacterial population size 
which was observed over the low and high MSM simulations. Another potential 
candidate for the identification of non-native SI flora and SIBO was the fructose CO2 
end-phase production quantities. Clear and quantified CO2 production increases 
between bacterial simulation scenarios (seen in fructose entries in Table 5.1) clearly 
demarcating the low-to-high SBM change, low SBM-to-low MSM change, and the low 
SBM-to-high MSM. Such quantified changes in CO2 production allow for clear 
identification of non-native SI flora and SIBO cases. The H2 production and production 
profiles did not show any notable trends or features that could uniquely identify non-
native SI flora or SIBO. The end-phase H2 production increases contains similar 
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percentage increases for SBM-MSM scenarios which made it difficult to uniquely 
identify. 
 
The bacterial growth assay demonstrated that the MSM profiles preferred glucose as a 
growth substrate. Conversely, the SBM simulations preferred the inulin. However, both 
bacterial models were in agreement that the fructose simulations were the least preferred 
growth medium. This result was confirmed with the very low H2 production quantities. 
 
The SCFA profiles measured at the end of the SI phase digestion reflected two unique 
profiles that were carbohydrate chain-length specific. For the mono-form carbohydrates, 
acetic acid produced quantities that were greater than double for the high MSM profiles. 
The use as acetic acid (and other SCFA’s) could be a biomarker for the detection of 
non-native SI flora and SIBO. 
 
Overall, the author’s in-vitro digestion simulator has demonstrated its ability to be used 
for the investigation of bacteria fermentation capacity within the upper gut for the 
purposes of identifying non-native SI flora and SIBO via the use of gas biomarkers. 
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Chapter 6 - Concluding remarks 
6.1  Concluding remarks 
 
The author’s aim in this PhD research was to address the gap in knowledge regarding 
the gas production mechanisms within the upper gastrointestinal tract with the idea of 
using them as biomarkers for assessing upper gut health outcomes. The use of in-vitro 
digestion systems is therefore considered as a powerful tool due to the digestion 
parameter customisability and low cost. In the author’s research, the demonstrated use 
of high sample rates for the observation of gas biomarkers can provide larger quantities 
of information that can be extracted from gas biomarkers than currently achieved via the 
use of real-time gas production profiles.  
 
As such, the author’s research was organised and pursued into three major stages in 
order to achieve the proposed research outcomes and to target the gaps in the current 
knowledge.  
 
In this PhD research, the author thoroughly investigated the literature on current gas 
measuring techniques by in-vitro digestion simulations and gas production 
measurements observed in the upper gastro-intestinal tract. At the time this PhD 
research started, in-vitro digestion simulators that measured gas species was done to 
solely observe bacterial fermentation behaviour and conducted as a single, total gas 
production measurement or recorded with long sampling periods ranging from 1 – 6 h 
per observation. Upper gastrointestinal in-vitro digestion simulations primarily focused 
their analyses on the food-chemistry, immunochemical, and pharmaceutical-gut 
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interactions. Therefore, within the first stage of this research, the author conducted an 
extensive investigation on the current in-vitro technologies and gas sensors that could 
meet the requirements of a multi-phase in-vitro digestion simulator for upper gut 
simulations. The gas sensors were also investigated to ensure that they adequately met 
the sensitivity range required to measure any gas produced within the simulations. The 
realised real-time gas monitoring upper gut in-vitro digestion simulator’s digestive 
outcomes was evaluated against the current available literature for the three well-studied 
carbohydrates: glucose; fructose and; inulin.  
 
In the second stage of this research, the author outlines the improvements made to the 
in-vitro digestion simulator and utilises a well-studied food-type whose food-matrix 
contains a complex mix of carbohydrates, lipids, and proteins – milk. A proof-of-
concept case study wherein gas bio-markers were used to investigate both chemical and 
bacterial gas productions outcomes. Trends and production patterns were aligned with 
current literature and clinical observations demonstrating the investigative and 
diagnostic potential for exploring gas production profiles for assessing gut disorders. 
 
In the third stage, the author investigates the gas production outcomes in a digestive 
simulated environment representing the upper gut disorder – SIBO. A more complex 
bacteria model (MSM) was introduced to emulate a non-native SI flora. The three 
model carbohydrates (from the first stage) was used as test stimulus to investigate a 
bacterial simulation matrix representing native (SBM) and non-native (MSM) SI flora 
versus low and high bacterial populations. The gas production and rate of production 
outcomes were investigated for key features and trends to identify changes in SI flora at 
both low and high bacteria levels.  
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As such, major achievements in each stage of this research are summarised as follows: 
 
6.1.1  Stage 1  
 
• An upper gut in-vitro digestion simulator was outlined and developed in the 
form of a modified static mono-compartment simulator that is capable of 
continuous gas monitoring and pH measurements. The simulation of successive 
digestive phases was achieved via custom machined Luer lock connector with a 
one-way check valve that fits into the septa port of a modified Schott bottle. The 
upper gut digestion protocols including ingredients for the simulated digestive 
fluids and suggested digestive phase timing was provided via Minkeus et al. [1]. 
The addition of an SBM was added to the digestion protocol to investigate the 
impact on gas production mechanisms.  
 
• The in-vitro digestion simulator’s gas sensing performance was assessed on the 
upper gut digestive outcomes of three well-studied model carbohydrates – 
glucose, fructose, and inulin. Real-time CO2 and H2 gas production profiles 
demonstrated trends, within the SI phase that clearly demarcate bacterial and 
non-bacterial production. This real-time gas production was used to determine 
the dominant source of gas production. 
 
• From the gastric real-time pH profiles observed for the model carbohydrate 
simulations, inulin pH was slightly higher than the glucose and fructose profiles. 
This slight alkalising trends (from time t = 0.5 to t = 2.0 h) throughout the gastric 
phase demonstrates the inulin slowly hydrolysing. Such a result was observed in 
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the literature by Nilsson et al. [2]. 
 
• Despite the gas production profiles and other digestive outcomes aligning with 
the current literature, the evaluation revealed several problems with the 
simulator including unstable H2 measurements and the difficulties in Raman and 
NMR analyses. Addressing these issues would largely improve the gas sensing 
and characterisations of the author’s upper gut in-vitro digestion simulation. 
 
 
6.1.2  Stage 2 
 
• The author first addresses the issues sighted from the previous research stage by 
modifying the TCD calorimetric sensor configuration to prioritise stability over 
sensitivity, increased quantities of food stimulus and simulated digesta fluids 
used in the simulations, and; extending the duration of the SI digestive phase to 
highlightboth chemical and bacterial influences. The result of these changes to 
the in-vitro simulator was observed in the milk digestion simulations with stable 
H2 measurements, increased qualitative Raman analysis demonstrating the milk-
matrix breakdown throughout the simulation, and; increased NMR analyses 
revealing quantitative measurements of SCFA and other metabolites.  
 
• Digestion simulation of the cow’s milk was used a proof-of-concept 
demonstration of the new iteration in-vitro digestion simulator. The gas 
production investigation was clearly able to identify the sources (chemical and 
bacterial) of production. Large CO2 productions for high bacterial simulations 
which did not include lactase which is aligned in clinical observations where 
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milk consumption resulted in bloating and excessive flatus. The introduction of 
lactase in the SI phase greatly reduces the CO2 production that was produced 
due to the presence of bacteria 39.8% - 46.1%.  
 
• Raman spectroscopy analysis was able to clearly demonstrate the milk food-
matrix breakdown throughout the three phases of digestion. The major 
macronutrients Raman peaks show decreasing magnitude through the digestion 
process. The impact of bacteria was also observed via Raman with glucose and 
galactose peaks significantly decreasing with the end-SI Raman spectrum. 
 
6.1.3  Stage 3 
 
• Based on the developments in the first two stages, the author of this thesis 
expanded the application of the real-time gas monitoring upper gut in-vitro 
digestion system to investigate gas production outcomes in a simulated SIBO 
digestive environment. Gas production outcomes of the three model 
carbohydrates (from stage 1) were investigated against an expanded bacteria 
model representing the bacterial communities are typically found within the 
lower gut where fermentation is dominant. The rate of production profiles was 
also introduced into this stage to further identify trends and key gas biomarker 
features. 
 
• The inulin carbohydrate CO2 rate of production profiles for the non-native SI 
flora demonstrate a unique ‘double peak’ feature in which the second peak 
scaled in magnitude with respect to the non-native SI bacteria population size.  
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• The use of SCFA analysis demonstrated bacterial fermentation trends with acetic 
acid as the largest by-product for mono-form carbohydrates (glucose and 
fructose). The second largest SCFA produced was butyric acid but trends 
towards propanoic acid with respect to the increasing population sizes of non-
native SI flora. As such, it could potentially be a bio-marker for the detection of 
non-native SI flora and SIBO. 
 
In conclusion, this research project has successfully brought new perspectives, 
knowledge and tools to in-vitro digestion simulations and the potential application of 
gas biomarkers within the upper gut for investigating and assessing potential gut 
disorders. A complete list of publications by the author during his PhD candidature is 
presented in the following sections. 
 
6.2  Journal publications 
The work conducted by the author of this dissertation during his PhD candidature, 
resulted in 7 journal publications. The list of author’s scientific manuscript and 
contributions is as follows: 
• Pillai, N., Berean, K.J., Brkljaca, R., Greve, L.J., Kasapis, S. and Kalantar-
zadeh, K., An in-vitro upper gut simulator for assessing continuous gas 
production: A proof-of-concept using milk digestion. Journal of Functional 
Foods, vol 47, page 200-210, 2018. 
 
• Kalantar-Zadeh, K., Berean, K.J., Ha, N., Chrimes, A.F., Xu, K., Grando, D., 
Ou, J.Z., Pillai, N., Campbell, J.L., Brkljača, R. and Taylor, K.M., A human 
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pilot trial of ingestible electronic capsules capable of sensing different gases in 
the gut. Nature Electronics, vol 1, page 79, 2018. 
o Contributed works – The use of the in-vitro digestion simulator to 
investigate O2 production via the ingestible electronic capsule within a 
simulated upper gut. The in-vitro digestion simulator observed an O2 
response in simulations that had selectively removing key digestion 
fluids and enzymes.   
 
• Kalantar-Zadeh, K., Yao, C.K., Berean, K.J., Ha, N., Ou, J.Z., Ward, S.A., 
Pillai, N., Hill, J., Cottrell, J.J., Dunshea, F.R. and McSweeney, C., Intestinal 
gas capsules: A proof-of-concept demonstration. Gastroenterology, vol 150(1), 
page 37-39, 2016. 
o Contributed works – Assistance in assembling gas capsules and data 
collection from animal testing.  
 
• Ou, J.Z., Cottrell, J.J., Ha, N., Pillai, N., Yao, C.K., Berean, K.J., Ward, S.A., 
Grando, D., Muir, J.G., Harrison, C.J. and Wijesiriwardana, U., Potential of in 
vivo real-time gastric gas profiling: a pilot evaluation of heat-stress and 
modulating dietary cinnamon effect in an animal model. Scientific reports, vol 6, 
article no. 33387, 2016. 
o Contributed works – In-situ pH measurements and collection of fresh 
samples taken from the pig gastrointestinal tract. Raman analysis was 
also conducted out on obtained samples. 
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• Mohiuddin, M., Pillai, N., Zavabeti, A., Mahmood, N., Syed, N., Datta, R.S., 
Jampaiah, D., Daeneke, T., Ou, J.Z. and Kalantar-Zadeh, K., Exploring electric 
field assisted van der Waals weakening of stratified crystals. Applied Materials 
Today, vol 12, page 359-365, 2018. 
o Contributed works - Creation and high-voltage electrical wiring of liquid 
exfoliation experiment jig.  
 
• Syed, N., Zavabeti, A., Ou, J.Z., Mohiuddin, M., Pillai, N., Carey, B.J., Zhang, 
B.Y., Datta, R.S., Jannat, A., Haque, F. and Messalea, K.A., Printing two-
dimensional gallium phosphate out of liquid metal. Nature communications, vol 
9(1), article no. 3618, 2018. 
o Contributed works – experimental equipment setup and edited draft 
manuscript and response-to-reviewers. 
 
• Daeneke, T., Dahr, N., Atkin, P., Clark, R.M., Harrison, C.J., Brkljača, R., 
Pillai, N., Zhang, B.Y., Zavabeti, A., Ippolito, S.J. and Berean, K.J., Surface 
water dependent properties of sulfur-rich molybdenum sulfides: electrolyteless 
gas phase water splitting. ACS nano, vol 11(7), page 6782-6794, 2017. 
o Contributed works – Measurement of moisture splitting by-products 
from sulfur-rich MoS2 using customised in-vitro simulation equipment.  
 
• Clark, R.M., Berean, K.J., Carey, B.J., Pillai, N., Daeneke, T., Cole, I.S., 
Latham, K. and Kalantar-Zadeh, K., Patterned films from exfoliated two-
dimensional transition metal dichalcogenides assembled at a liquid–liquid 
interface. Journal of Materials Chemistry C, 5(28), page 6937-6944, 2017 
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o Contributed works – Photolithographic formation and dicing of Si/SiO2 
patterns used in the patterned film formation. 
 
6.3  Recommendations for future work 
In order for furthering the knowledge arising from upper gut in-vitro digestion systems 
and their associated applications, a number of suggestions for further expansion to 
address in-vitro limitations could be made. In this PhD research, author demonstrated an 
upper gut in-vitro technology that can measure real-time gas production and pH 
profiles. However, two areas of interest that would increase the digestive outcomes and 
better link the in-vitro – in-vivo analyses are presented as follows: 
 
• Oro-caecal transient time based on simulated digestive fluid profiles. As the 
food bolus or digesta enters the next stage of digestion, the simulated digestives 
are ‘slowly’ introduced into the digestive organ [3]. The representation of the 
orocecal transit time is an important digestion parameter that changes with food-
types and size of meal [4, 5]. There has been attempts to simulate this in-vitro 
[6] via a multi-compartment variation but could be simplified into a single 
compartment in-vitro digestion simulator.  
 
• The addition of SI phase nutrient absorption into the simulation. Another 
important aspect that would improve the digestion simulator outcomes, 
especially within the SI phase of simulations, is the nutrient absorption 
mechanism. In the third stage of research, the mono-form carbohydrates 
demonstrated individual and unique responses to the non-native SI flora 
environment. However, the emulation of nutrient absorption would have 
provided a more in vitro- in vivo relatable digestive outcome [7]. There are a few 
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in-vitro simulation systems that have attempted to simulate nutrient absorption 
[7-9]. However, the adaption to the mono-compartment simulator would 
significantly increase the in-vitro digestion simulators potential application and 
would add significant impact for its use. Furthermore, this increases the in-vitro 
– in-vivo link making digestive outcomes more relatable. 
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